

# CITATION REPORT

List of articles citing

**Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis**

**DOI: 10.7326/0003-4819-131-7-199910050-00003**  
**Annals of Internal Medicine, 1999, 131, 492-501.**

**Source:** <https://exaly.com/paper-pdf/30663318/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1217	Atrial fibrillation: the epidemic of the new millennium. <i>Annals of Internal Medicine</i> , <b>1999</b> , 131, 537-8	8	46
1216	Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. <i>Annals of Internal Medicine</i> , <b>1999</b> , 131, 688-95	8	179
1215	Preventing ischemic stroke. Current approaches to primary and secondary prevention. <b>2000</b> , 107, 34-6, 39-42, 47-50		15
1214	Prevention of ischaemic stroke. <b>2000</b> , 321, 1455-9		32
1213	Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. <b>2000</b> , 31, 1217-22		99
1212	Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm. <b>2001</b> , CD003333		8
1211	Secondary stroke prevention in atrial fibrillation: lessons from clinical practice. <b>2000</b> , 31, 2106-11		56
1210	Development of a decision aid for atrial fibrillation who are considering antithrombotic therapy. <b>2000</b> , 15, 723-30		28
1209	Stroke prevention in atrial fibrillation. <b>2000</b> , 2, 51-5		20
1208	Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. <b>2000</b> , 109, 45-51		75
1207	Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. <b>2000</b> , 355, 956-62		144
1206	Cost effectiveness of therapies for atrial fibrillation. A review. <b>2000</b> , 18, 317-33		7
1205	Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. <b>2000</b> , 35, 183-7		507
1204	Epidemiology and natural history of atrial fibrillation: clinical implications. <b>2001</b> , 37, 371-8		575
1203	ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation)		54
1202	ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With		634
1201	Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. <b>2001</b> , 358, 1033-41		2580

1200	Antithrombotic and thrombolytic therapy for ischemic stroke. <b>2001</b> , 17, 149-61	5
1199	Perioperative management and reversal of antithrombotic therapy. <b>2001</b> , 17, 189-202, ix	10
1198	ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Non-valvular atrial fibrillation and stroke prevention. National Blood Pressure Advisory Committee of the National Heart Foundation. <b>2001</b> , 174, 234-9	747
1197	ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Non-valvular atrial fibrillation and stroke prevention. National Blood Pressure Advisory Committee of the National Heart Foundation. <b>2001</b> , 174, 234-9	41
1196	Anticoagulation in the elderly. <b>2001</b> , 7, 365-70	10
1195	The fight against stroke: victories, defeats, strategies. <b>2001</b> , 14, 55-7	
1194	The ten most commonly asked questions about stroke prevention in atrial fibrillation. <b>2001</b> , 9, 187-92	1
1193	. <b>2001</b> , 8, 307-309	
1192	Antithrombotic therapy in atrial fibrillation. <b>2001</b> , 119, 194S-206S	363
1191	Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. <b>2001</b> , CD001938	16
1190	Compliance with secondary prevention of ischemic stroke: a prospective evaluation. <b>2001</b> , 32, 1884-9	100
1189	Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. <b>2001</b> , 322, 321-6	77
1188	Atrial fibrillation and stroke : concepts and controversies. <b>2001</b> , 32, 803-8	260
1187	The sin of omission: a systematic review of antithrombotic therapy to prevent stroke in atrial fibrillation. <b>2001</b> , 49, 91-4	9
1186	In reply. <b>2001</b> , 49, 96-97	
1185	Outcomes in the management of atrial fibrillation: clinical trial results can apply in practice. <b>2001</b> , 31, 329-36	54
1184	Targeting patients with atrial fibrillation and improving their anticoagulation management. <b>2001</b> , 24, 355-7	1
1183	Adequacy of anticoagulation in patients with atrial fibrillation: effect of various parameters. <b>2001</b> , 24, 380-4	4

1182	Atrial fibrillation and antithrombotic treatment in Italian hospitalized patients: a prospective, observational study. <b>2001</b> , 12, 225-30	11
1181	Limited evidence for the benefits of anticoagulation treatment for non-rheumatic atrial fibrillation. <b>2001</b> , 5, 79-80	
1180	Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database. <b>2001</b> , 86, 284-8	189
1179	Hemorrhagic complications of anticoagulant treatment. <b>2001</b> , 119, 1085-1215	415
1178	Atrial fibrillation in the elderly--an increasing problem that mandates aggressive management. <b>2001</b> , 10, 289-92	1
1177	Use of antihypertensive and antithrombotic medications after stroke in community-based care. <b>2001</b> , 35, 811-6	9
1176	Preventing stroke: is preventing microemboli enough?. <b>2001</b> , 103, 2321-2	10
1175	Atrial fibrillation in the elderly: anticoagulation strategies and indications in the very elderly. <b>2002</b> , 11, 357-62; quiz 363-4	8
1174	Development and description of a decision analysis based decision support tool for stroke prevention in atrial fibrillation. <b>2002</b> , 11, 25-31	31
1173	Physicians' and patients' choices in evidence based practice. <b>2002</b> , 324, 1350	287
1172	Case report of paroxysmal atrial fibrillation and anticoagulation. <b>2002</b> , 325, 1018-20	2
1171	Warfarin therapy for atrial fibrillation in the elderly. <b>2002</b> , 36, 200-4	20
1170	Patent foramen ovale and recurrent stroke: another paradoxical twist. <b>2002</b> , 105, 2580-2	31
1169	Selection of endpoints in atrial fibrillation studies. <b>2002</b> , 13, S47-52	13
1168	Benefits of a mobile, point-of-care anticoagulation therapy management program. <b>2002</b> , 28, 625-30	11
1167	Aspirin in the prophylaxis of coronary artery disease. <b>2002</b> , 17, 552-8	32
1166	Adherence to practice guidelines for transient ischemic attacks in an emergency department. <b>2002</b> , 29, 358-63	17
1165	Prevalence of atrial fibrillation and antithrombotic prophylaxis in emergency department patients. <b>2002</b> , 33, 2664-9	53

1164	Stroke severity in patients with atrial fibrillation. <b>2002</b> , 112, 572-4	17
1163	A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. <b>2002</b> , 113, 359-64	1087
1162	A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. <b>2002</b> , 40, 484-90	60
1161	A benefit-risk assessment of agents used in the secondary prevention of stroke. <b>2002</b> , 25, 943-63	3
1160	Secondary prevention of stroke: old and new evidence. <b>2002</b> , 14, 216-20	4
1159	Atrial fibrillation: strategies to control, combat, and cure. <b>2002</b> , 359, 593-603	110
1158	Electrode positioning for cardioversion of atrial fibrillation. <b>2002</b> , 360, 1263-4	4
1157	Atrial Fibrillation. <b>2002</b> , 30, 140-144	
1156	Trends in case-fatality in 22968 patients admitted for the first time with atrial fibrillation in Scotland, 1986-1995. <b>2002</b> , 82, 229-36	31
1155	Use of cardiovascular medications in the elderly. <b>2002</b> , 85, 203-15	32
1154	Oral Anticoagulation in Nursing Home Residents. <b>2002</b> , 3, 21-22	1
1153	Neurologic manifestations of cardiogenic embolism: an update. <b>2002</b> , 20, 179-93, vii	36
1152	Addressing the heterogeneity of the ischemic stroke phenotype in human genetics research. <b>2002</b> , 33, 2770-4	42
1151	Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. <b>2002</b> , 33, 1763-71	160
1150	Aspirin should be first-line antiplatelet therapy in the secondary prevention of stroke. <b>2002</b> , 33, 2137-8	14
1149	Optimising Stroke Outcomes through Evidence-Based Nursing Practice: An Australian Perspective. <b>2002</b> , 1, 227-235	1
1148	Atrial Fibrillation in the 21st Century: The New Cardiac "Cinderella" and New Horizons for Cardiovascular Nursing?. <b>2002</b> , 1, 115-121	1
1147	Echocardiography in search of a cardioembolic source. <b>2002</b> , 27, 342-58	4

1146	Selection of anticoagulants or antiplatelet-aggregating agents for prevention of stroke. <b>2002</b> , 2, 31-7	2
1145	Treatment and monitoring of patients with antiphospholipid antibodies and thrombotic history (Hughes syndrome). <b>2002</b> , 4, 392-8	7
1144	Determination of the clinical importance of study results. <b>2002</b> , 17, 469-76	109
1143	The use of oral anticoagulants (warfarin) in older people. American Geriatrics Society guideline. <b>2002</b> , 50, 1439-45; discussion 1446-7	38
1142	Atrial fibrillation in a primary care practice: prevalence and management. <b>2002</b> , 3, 11	20
1141	The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. <b>2002</b> , 11, 569-76	40
1140	Clinical Expertise in the Era of Evidence-Based Medicine and Patient Choice (editorial). <b>2002</b> , 83, 383-386	33
1139	Anticoagulants for atrial fibrillation: why is the treatment rate so low?. <b>2002</b> , 25, 447-54	57
1138	Physicians' attitudes and the use of oral anticoagulants: surveying the present and envisioning future. <b>2003</b> , 16, 33-7	8
1137	[Therapy of atrial fibrillation]. <b>2003</b> , 44, 719-20, 723-6, 729-31; quiz 732	0
1136	Antithrombotic and thrombolytic therapy for ischemic stroke. <b>2003</b> , 5, 267-75	0
1135	[Adequate anticoagulation in atrial fibrillation]. <b>2003</b> , 44, 1330-1	
1134	Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269]. <b>2003</b> , 3, 9	23
1133	The Ischemic Stroke Genetics Study (ISGS) Protocol. <b>2003</b> , 3, 4	43
1132	Prescribing patterns and outcomes of enoxaparin for anticoagulation of atrial fibrillation. <b>2003</b> , 23, 651-8	9
1131	[Factors influencing secondary prevention of atherothrombotic disease in the private outpatient cardiology setting: results of the Prisma survey]. <b>2003</b> , 52, 20-9	4
1130	Atrial fibrillation or flutter and stroke: effectiveness of oral anticoagulation in clinical practice. <b>2003</b> , 253, 92-3	
1129	Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. <b>2003</b> , 254, 95-101	41

1128	Unresolved issues in anticoagulant therapy. <b>2003</b> , 1, 1464-70	35
1127	Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues. <b>2003</b> , 14, S60-3	27
1126	Prevention of vascular events in patients with atrial fibrillation: evidence, guidelines, and practice. <b>2003</b> , 14, S52-5	6
1125	Percutaneous closure of the left atrial appendage. <b>2003</b> , 16, 553-6	18
1124	[Use of oral anticoagulants in patients discharged with atrial fibrillation in 2000]. <b>2003</b> , 56, 1057-63	4
1123	Factores de riesgo e ictus en pacientes de diferentes edades. <b>2003</b> , 203, 189-192	2
1122	Total artificial hearts: bridge to transplantation. <b>2003</b> , 21, 101-13	82
1121	Oral Anticoagulation in Nursing Home Residents. <b>2003</b> , 4, S50-S51	
1120	DVT prophylaxis and anticoagulation in the surgical patient. <b>2003</b> , 87, 77-110, viii	35
1119	[Patterns of clinical presentation of atrial fibrillation in hospitalized patients]. <b>2003</b> , 56, 1187-94	4
1118	[Consensus document for the management of patients with atrial fibrillation in hospital emergency departments]. <b>2003</b> , 56, 801-16	7
1117	Aspirin for the prevention of cardiovascular events in the elderly. <b>2003</b> , 20, 999-1010	16
1116	Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. <b>2003</b> , 41, 1445-51	167
1115	Session. <b>2003</b> , 146, 24-25	1
1114	Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). <b>2003</b> , 146, 431-8	180
1113	Atrial fibrillation as a risk factor for stroke recurrence. <b>2003</b> , 114, 206-10	74
1112	Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. <b>2003</b> , 34, 1710-6	265
1111	Medical indications and considerations for future clinical decision making. <b>2003</b> , 109 Suppl 1, S31-7	10

1110	[Oral anticoagulants in the elderly]. <b>2003</b> , 24, 107-17	3
1109	Stroke. <b>2003</b> , 362, 1211-24	332
1108	Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. <b>2003</b> , 362, 1691-8	676
1107	IGF-I activity may be a key determinant of stroke risk--a cautionary lesson for vegans. <b>2003</b> , 61, 323-34	10
1106	Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. <b>2003</b> , 349, 1019-26	950
1105	Cardiovascular drug therapy in the elderly: theoretical and practical considerations. <b>2003</b> , 20, 445-63	20
1104	Review of the current management of atrial fibrillation. <b>2003</b> , 4, 1889-99	
1103	Atrial fibrillation: relation between clinical risk factors and transoesophageal echocardiographic risk factors for thromboembolism. <b>2003</b> , 89, 165-8	24
1102	Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. <b>2003</b> , 107, 3141-5	226
1101	Evaluation of Anticoagulation Therapy in an Academic Nursing Home. <b>2003</b> , 19, 141-145	3
1100	The Use of Oral Anticoagulants (Warfarin) in Older People. <b>2003</b> , 12, 153-177	
1099	Atrial fibrillation and the hypercoagulable state: from basic science to clinical practice. <b>2003</b> , 33, 282-9	84
1098	Clinical practice. Care of patients receiving long-term anticoagulant therapy. <b>2003</b> , 349, 675-83	183
1097	Rate or rhythm control in persistent atrial fibrillation?. <b>2003</b> , 96, 881-92	21
1096	International Society of Hypertension (ISH). <b>2003</b> , 21, 651-663	36
1095	Quality of Prescribing for Elderly Inpatients at Nine Hospitals in Victoria, Australia. <b>2003</b> , 33, 101-105	10
1094	Anticoagulants for preventing recurrence following ischaemic stroke or transient ischaemic attack. <b>2000</b> , CD000248	11
1093	Inhibition of factor Xa reduces ischemic brain damage after thromboembolic stroke in rats. <b>2003</b> , 34, 468-74	21



1092	The beginning of the end of warfarin?. <b>2004</b> , 180, 549-51	7
1091	Hypertension and stroke. <b>2004</b> , 225-234	
1090	Role of oral anticoagulation in management of atrial fibrillation. <b>2004</b> , 90, 813-7	25
1089	A community-based educational intervention to improve antithrombotic drug use in atrial fibrillation. <b>2004</b> , 38, 1794-9	33
1088	Long-term management of patients after venous thromboembolism. <b>2004</b> , 110, 110-8	80
1087	The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <b>2004</b> , 126, 204S-233S	852
1086	Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. <b>2004</b> , 110, 2287-92	616
1085	Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation?. <b>2004</b> , 35, 389-91	13
1084	Atrial fibrillation and the urologist. <b>2004</b> , 94, 254-5	2
1083	Accuracy and clinical usefulness of the near-patient testing CoaguChek S international normalised ratio monitor in rural medical practice. <b>2004</b> , 12, 137-42	22
1082	Atrial fibrillation and thrombosis: immunohistochemical differences between in situ and embolized thrombi. <b>2004</b> , 2, 1637-44	55
1081	Should aspirin be continued in patients started on warfarin?. <b>2004</b> , 19, 879-86	33
1080	Accuracy, reproducibility and clinical utility of the CoaguChek S portable international normalized ratio monitor in an outpatient anticoagulation clinic. <b>2004</b> , 26, 49-55	21
1079	Warfarin for atrial fibrillation: the end of an era?. <b>2004</b> , 3, 305-8	25
1078	A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643]. <b>2004</b> , 4, 5	11
1077	The role of oral direct thrombin inhibitors in atrial fibrillation. <b>2004</b> , 24, 190S-198S	
1076	L'hypertension artérielle et un âge de plus de 70 ans sont les principaux facteurs de risque d'accidents vasculaires cérébraux chez les patients en fibrillation auriculaire. <b>2004</b> , 53, 18-22	
1075	Strategies for perioperative arrhythmias. <b>2004</b> , 18, 565-77	13

1074	Trombocytenuaggregatieremming of antistolling?acetylsalicylzuur trombocytenuaggregatieremmers antistollingsmiddelen hart- en vaatziekten. <b>2004</b> , 20, 40-43	1
1073	Do population studies confirm the benefit of oral anticoagulation in atrial fibrillation demonstrated in clinical trials?. <b>2004</b> , 10 Suppl 1, 9-16	7
1072	Why is warfarin underutilized in patients with atrial fibrillation?. <b>2004</b> , 10 Suppl 1, 21-5	6
1071	Trials of newer approaches to anticoagulation in atrial fibrillation. <b>2004</b> , 10 Suppl 1, 27-31	2
1070	Alternatives to warfarin for thromboembolism prophylaxis in nonrheumatic atrial fibrillation. <b>2004</b> , 10 Suppl 1, 33-44	2
1069	The decision to anticoagulate: assessing whether benefits outweigh the risks for patients with atrial fibrillation. <b>2004</b> , 27, 313-20	5
1068	[Risk factors in ischemic stroke. Review of evidence in primary prevention]. <b>2004</b> , 75, 324-35	4
1067	New approaches to anticoagulation in atrial fibrillation. <b>2004</b> , 6, 354-64	4
1066	Anticoagulation for non-valvular atrial fibrillation - towards a new beginning with ximelagatran. <b>2004</b> , 5, 3	4
1065	Occurrence and quality of anticoagulant treatment of chronic atrial fibrillation in primary health care in Sweden: a retrospective study on electronic patient records. <b>2004</b> , 4, 1	16
1064	Impact of age on the outcome of pulmonary vein isolation for atrial fibrillation using circular mapping technique and cooled-tip ablation catheter:. <b>2004</b> , 15, 8-13	81
1063	Risk factors for stroke and thromboprophylaxis in atrial fibrillation: what happens in daily clinical practice? The GEFAUR-1 study. <b>2004</b> , 44, 3-11	34
1062	The increasing need for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. <b>2004</b> , 79, 904-13	31
1061	Evidence-Based Medicine: Is It Relevant to Long-Term Care?. <b>2004</b> , 5, 328-332	17
1060	Anticoagulation for atrial fibrillation. <b>2004</b> , 22, 47-62	9
1059	[Anticoagulants for patients with chronic auricular fibrillation: when are they indicated?]. <b>2004</b> , 34, 374-8	0
1058	Economic implications of transesophageal echocardiography-guided cardioversion of atrial fibrillation. <b>2004</b> , 43, 1225-7	1
1057	Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. <b>2004</b> , 44, 1557-66	176

1056	Anticoagulation influences long-term outcome in patients with nonvalvular atrial fibrillation and severe ischemic stroke. <b>2004</b> , 2, 265-73	5
1055	Socioeconomic Implications of Long-Term Warfarin Use. <b>2004</b> , 12, 385-392	
1054	Clinical practice. Newly diagnosed atrial fibrillation. <b>2004</b> , 351, 2408-16	95
1053	Effect of intravenous heparin administration on duration of hospitalization. <b>2004</b> , 79, 159-63	10
1052	Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor. <b>2004</b> , 2, 163-74	6
1051	Detection of atrial fibrillation in patients with acute stroke. <b>2004</b> , 13, 12-5	19
1050	AHJ at the meetings. <b>2004</b> , 147, 610-611	
1049	The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis. <b>2004</b> , 116, 451-9	22
1048	Anticoagulation en cas de fibrillation auriculaire : quelle dose efficace et bien tol��e pour r��duire le risque d'��v��nement vasculaire c��r��bral ?. <b>2004</b> , 33, 295	
1047	First-generation agents: aspirin, heparin and coumarins. <b>2004</b> , 17, 23-53	22
1046	Ximelagatran or warfarin in atrial fibrillation?. <b>2004</b> , 363, 735-6; author reply 736	1
1045	Ximelagatran or warfarin in atrial fibrillation?. <b>2004</b> , 363, 736	4
1044	Improving patients' safety locally: changing clinician behaviour. <b>2004</b> , 363, 1224-30	93
1043	Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. <b>2004</b> , CD000187	44
1042	A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor. <b>2004</b> , 44, 1063-71	15
1041	Progress in clinical neurosciences: pharmacotherapies for the secondary prevention of stroke. <b>2004</b> , 31, 295-303	1
1040	A new solution for an old problem? Effects of a nurse-led, multidisciplinary, home-based intervention on readmission and mortality in patients with chronic atrial fibrillation. <b>2004</b> , 19, 118-27	33
1039	Atrial fibrillation in the heart failure population. <b>2004</b> , 19, S3-10	3

1038	Epidemiology and economic impact of atrial fibrillation. <b>2004</b> , 19, 94-102	15
1037	Common Questions About Cardiac Care. <b>2004</b> , 22, 83-84	
1036	Applying the grades of recommendation for antithrombotic and thrombolytic therapy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <b>2004</b> , 126, 179S-187S	70
1035	Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <b>2004</b> , 126, 429S-456S	427
1034	Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <b>2004</b> , 126, 287S-310S	361
1033	Arrhythmia Management in the Elderly. <b>2005</b> , 261-300	1
1032	Stroke prevention in atrial fibrillation: the case for ximelagatran. <b>2005</b> , 7, E21-E25	2
1031	In defence of current treatment options: where are we now?. <b>2005</b> , 7, E4-E9	4
1030	Anticoagulation: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. <b>2005</b> , 128, 24S-27S	64
1029	Intracerebral hemorrhage. <b>2005</b> , 11, 311-24	53
1028	Ximelagatran Cost Effectiveness for Stroke Prevention in Atrial Fibrillation. <b>2005</b> , 35, 279-283	1
1027	Rehospitalization and survival for stroke patients in managed care and traditional Medicare plans. <b>2005</b> , 43, 902-10	41
1026	Anticoagulation as thromboprophylaxis for atrial fibrillation: implications in the 'real world' and the need for risk stratification. <b>2005</b> , 16, 461-4	2
1025	Differences in quality of care among patients hospitalized with atrial fibrillation as primary or secondary cause for admission. <b>2005</b> , 17, 255-8	6
1024	Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation. <b>2005</b> , 7, C41-C54	7
1023	A preliminary assessment of the critical differences between novel oral anticoagulants currently in development. <b>2005</b> , 45, 1004-17	14
1022	Rate control versus rhythm control. <b>2005</b> , 4, 205-210	
1021	Differences among clinical classification schemes for predicting stroke in atrial fibrillation: implications for therapy in daily practice. <b>2005</b> , 12, 828-34	7

1020	Antithrombotic strategies for atrial fibrillation: on the threshold of changes? Yes. <b>2005</b> , 3, 428-32	5
1019	Antithrombotic strategies for atrial fibrillation: on the threshold of changes? No. <b>2005</b> , 3, 433-5	
1018	Preventable stroke and stroke prevention. <b>2005</b> , 3, 1638-45	36
1017	Atherothrombosis: management of patients at risk. <b>2005</b> , 59, 407-14	4
1016	Frequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillation. <b>2005</b> , 258, 133-44	55
1015	Rhythm vs. rate control of atrial fibrillation meta-analysed by number needed to treat. <b>2005</b> , 60, 347-54	27
1014	Antithrombotic therapy for stroke prevention in atrial fibrillation. <b>2005</b> , 48, 108-24	9
1013	Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system. <b>2005</b> , 5, 25	193
1012	An evidence-based causative classification system for acute ischemic stroke. <b>2005</b> , 58, 688-97	483
1011	[Pharmacological cardioversion of atrial fibrillation]. <b>2005</b> , 94, 14-22	3
1010	Current treatments in neurology: stroke. <b>2005</b> , 252, 260-7	7
1009	New treatment options for stroke prevention in atrial fibrillation. <b>2005</b> , 7, 341-9	
1008	Concomitant drug, dietary, and lifestyle issues in patients with atrial fibrillation receiving anticoagulation therapy for stroke prophylaxis. <b>2005</b> , 7, 241-50	4
1007	Atrial fibrillation and stroke: four treatment controversies. <b>2005</b> , 7, 491-8	1
1006	Prevention of embolism among patients with atrial fibrillation. <b>2005</b> , 5, 9-12	
1005	Timing and Typology of Cardio-Embolic Prevention in Patients with Atrial Fibrillation. <b>2005</b> , 107-114	
1004	Impact of a patient decision aid on care among patients with nonvalvular atrial fibrillation: a cluster randomized trial. <b>2005</b> , 173, 496-501	70
1003	Preference-based antithrombotic therapy in atrial fibrillation: implications for clinical decision making. <b>2005</b> , 25, 548-59	57

1002	Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation. <b>2005</b> , 81, 370-5	1
1001	Oral anticoagulation for atrial fibrillation after ST-elevation myocardial infarction: new evidence to guide clinical practice. <b>2005</b> , 112, 3212-4	13
1000	Prognostic implications of warfarin cessation after major trauma: a population-based cohort analysis. <b>2005</b> , 111, 2250-6	17
999	Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: a prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). <b>2005</b> , 112, 3225-31	78
998	Anticoagulation in nonvalvular atrial fibrillation. <b>2005</b> , 1, 373-80	1
997	Acute anticoagulation adjustment in patients with atrial fibrillation at risk for stroke: approaches, strategies, risks and benefits. <b>2005</b> , 3, 571-90	2
996	Atrial fibrillation: management for the geriatric patient. <b>2005</b> , 14, 242-7; quiz 248-9	2
995	Rate control vs. rhythm control in the management of atrial fibrillation in elderly persons. <b>2005</b> , 14, 73-8; quiz 79-80	6
994	Anticoagulation for atrial fibrillation in the elderly. <b>2005</b> , 14, 81-6	5
993	Rate versus rhythm control in the management of patients with atrial fibrillation. <b>2005</b> , 2, 514-21	18
992	Patients' perceptions regarding oral anticoagulation therapy and its effect on quality of life. <b>2005</b> , 21, 1085-90	48
991	Emerging role of direct thrombin inhibitors in nonvalvular atrial fibrillation: potential and peril. <b>2005</b> , 10, 11-21	7
990	Clinical trials: advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. <b>2005</b> , 14, 98-9	
989	Antithrombotic management after an ischemic stroke in French primary care practice: results from three pooled cross-sectional studies. <b>2005</b> , 20, 78-84	10
988	Perioperative management of patients on oral anticoagulants: a decision analysis. <b>2005</b> , 25, 387-97	24
987	Intra-arterial thrombolysis in patients treated with warfarin. <b>2005</b> , 19, 133-5	14
986	Prevention of stroke in patients with diabetes mellitus and the metabolic syndrome. <b>2005</b> , 20 Suppl 1, 24-34	17
985	Should ximelagatran replace warfarin for stroke prevention in patients with atrial fibrillation?. <b>2005</b> , 2, 278-9	

984	Comparison of stroke risk factors and outcomes in patients with English-speaking background versus non-English-speaking background. <b>2005</b> , 24, 79-86	10
983	Current issues in anticoagulation. <b>2005</b> , 34 Suppl 1, 2-9	18
982	Preventing stroke in atrial fibrillation: the SPORTIF programme. <b>2005</b> , 34 Suppl 1, 25-30	8
981	Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated?. <b>2005</b> , 36, 360-6	82
980	Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack. <b>2005</b> , 36, 2164-9	92
979	Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine. <b>2005</b> , 36, 2159-63	60
978	Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study. <b>2005</b> , 36, 2362-6	82
977	Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. <b>2005</b> , 21, 1583-94	51
976	Nonpharmacologic stroke prevention in atrial fibrillation. <b>2005</b> , 3, 619-33	41
975	Current status of stroke prevention in patients with atrial fibrillation. <b>2005</b> , 7, C12-C18	5
974	Emerging therapies for stroke prevention in atrial fibrillation. <b>2005</b> , 7, C19-C27	3
973	Indication for antithrombotic therapy for atrial fibrillation: reconciling the guidelines with clinical practice. <b>2005</b> , 7, C28-C33	5
972	Reversal of anticoagulation in trauma: a North-American survey on clinical practices among trauma surgeons. <b>2005</b> , 59, 375-82	12
971	Estudio de prevalencia de la fibrilaci3n auricular en la poblaci3n de 65 a3os o m3s. Validez de la toma de pulso radial como cribado de fibrilaci3n auricular. <b>2005</b> , 31, 303-306	1
970	[Age, an independent risk factor for thrombosis. Epidemiologic data]. <b>2005</b> , 34, 878-86	4
969	[Preventing cerebrovascular accidents during atrial fibrillation]. <b>2005</b> , 34, 1315-24	4
968	Enfermedad cerebrovascular (II): tratamiento, prevenci3n secundaria y rehabilitaci3n. <b>2005</b> , 12, 11-27	
967	Estudio de prevalencia de la fibrilaci3n auricular en la poblaci3n de 65 a3os o m3s. Validez de la toma de pulso radial como cribado de fibrilaci3n auricular. <b>2005</b> , 31, 303-306	

966	[Antiphospholipid syndrome treatment, to whom, when and how long?]. <b>2005</b> , 1 Suppl 2, S52-8	1
965	How many patients in atrial fibrillation admitted to an acute medical unit will benefit from oral anticoagulation? Application of the results of the major randomized controlled trials to 141 consecutive, unselected, elderly patients using a decision support computer program. <b>2005</b> , 16, 97-104	1
964	Strategies for stroke prevention in atrial fibrillation. <b>2005</b> , 2, 103-6	3
963	[Antithrombotic drugs in the prevention of ischemic stroke]. <b>2005</b> , 30, 267-79	
962	Digoxin and increased risk of stroke in patients with atrial fibrillation. <b>2005</b> , 2, 530-1	2
961	Pharmacological Treatment for Atrial Fibrillation. <b>2005</b> , 21, 358-370	
960	Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. <b>2005</b> , 36, 1588-93	291
959	Anticoagulation during cardioversion in patients with atrial fibrillation: current clinical practice. <b>2005</b> , 5, 155-62	2
958	Antithrombotic strategies for the management of non-valvular atrial fibrillation. <b>2005</b> , 100, 191-8	6
957	Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. <b>2005</b> , 150, 288-93	354
956	Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril. <b>2005</b> , 150, 985	2
955	[Auricular fibrillation as a risk factor of cerebrovascular events in the over-65s. Is clinical practice in anticoagulant prophylaxis adequate?]. <b>2005</b> , 36, 198-203	2
954	Pharmacologic therapies for atrial fibrillation. <b>2005</b> , 14, 62-7	3
953	Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study. <b>2005</b> , 39, 446-51	65
952	Hepatic findings in long-term clinical trials of ximelagatran. <b>2005</b> , 28, 351-70	134
951	Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation. <b>2005</b> , 45, 1-9	30
950	Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. <b>2005</b> , 46, 1729-36	305
949	Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. <b>2005</b> , 46, 1913-20	326



948 Traitement médical des troubles du rythme. **2005**, 2, 388-397

947 Atrial fibrillation. **2005**, 32, 1083-107

2

946 Prevention of cardiovascular events in elderly people. **2005**, 22, 859-76

56

945 Ximelagatran for stroke prevention in atrial fibrillation. **2005**, 3, 551-63

3

944 To anticoagulate or not to anticoagulate? A common dilemma for the provider: physicians' opinion poll based on a case study of an older long-term care facility resident with dementia and atrial fibrillation. **2006**, 7, 23-8

44

943 Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery. **2006**, 30, 852-72

129

942 The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. **2006**, 24, 1021-33

112

941 Anticoagulation for stroke prevention: high effectiveness, more cost benefit?. **2006**, 24, 1035-8

940 The risks of warfarin use in the elderly. **2006**, 5, 417-31

12

939 Atrial fibrillation and stroke prevention. **2006**, 6, 1523-30

3

938 [Use and monitoring of vitamin K antagonists in everyday medical practice. French results of the international ISAM study of patients with nonvalvular atrial fibrillation]. **2006**, 35, 1797-803

8

937 Stroke prevention in patients with atrial fibrillation: the diagnosis and management of hypertension by specialists. **2006**, 22, 485-8

7

936 Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. **2006**, 367, 1903-12

1462

935 Quality improvement case study: warfarin sodium interactions. **2006**, 7, 315-8

3

934 Antithrombotic and thrombolytic therapy for ischemic stroke. **2006**, 22, 135-54, ix-x

4

933 Antithrombotic therapy in atrial fibrillation. **2006**, 22, 155-66, x

6

932 Les antithrombotiques dans la prévention des accidents ischémiques cérébraux. **2006**, 26, 67-77

931 Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. **2006**, 22, 17-32, vii-viii

30

930	Compliance-guided therapy : a new insight into the potential role of clinical pharmacologists. <b>2006</b> , 45, 95-104	11
929	ACC/AHA/ESC: Guías de Práctica Clínica 2006 para el manejo de pacientes con fibrilación auricular. Versión resumida. <b>2006</b> , 59, 1329.e1-1329.e64	2
928	Trials and tribulations of noninferiority: the ximelagatran experience. <b>2006</b> , 48, 1058; author reply 1059	4
927	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines	865
926	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to	261
925	Revised the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Pacific Heart Society. <b>2006</b> , 152, 967-73	138
924	Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. <b>2006</b> , 119, 607-15	68
923	A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: there remains an unmet need. <b>2006</b> , 151, 771-8	47
922	Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. <b>2006</b> , 151, 1187-93	83
921	Pharmacotherapy for patients undergoing carotid stenting. <b>2006</b> , 60, 14-9	6
920	Antiplatelet versus anticoagulant therapies in advanced age: an unfinished task. <b>2006</b> , 110, 271-2	3
919	Thromboembolism and anticoagulant management in hemodialysis patients: a practical guide to clinical management. <b>2006</b> , 118, 385-95	34
918	Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. <b>2006</b> , 118, 321-33	174
917	Stroke: epidemiology, classification, risk factors, complications, diagnosis, prevention, and medical and dental management. <b>2006</b> , 102, 180-91	36
916	WITHDRAWN: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. <b>2007</b> , CD001938	2
915	Is low-dose aspirin a safe and effective option for primary stroke prevention in patients with atrial fibrillation?. <b>2006</b> , 3, 248-249	
914	Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. <b>2006</b> , 332, 141-5	123
913	Traitement médical des troubles du rythme. <b>2006</b> , 1, 1-7	

912 Causes cardiaques d'embolie c brale. **2006**, 3, 1-23

911 Response to Letter by Testa et al. **2006**, 37, 2868-2868

910 D-dimer is not a long-term prognostic marker following acute cerebral ischemia. **2006**, 17, 303-6 24

909 Thromboprophylaxis in atrial fibrillation: why, how, when and how can we do better?. **2006**, 60, 252-5 1

908 Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review. **2006**, 4, 1180-5 23

907 A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: the Rotterdam Study 1990-1999. **2006**, 4, 1944-9 52

906 Ximelagatran, the new oral anticoagulant: would warfarin survive the challenge?. **2005**, 23, 331-44 3

905 A study of the safety of continued anticoagulation for cataract surgery patients. **2006**, 41, 30-7 12

904 Incidence of atrial tachyarrhythmias in pacemaker patients: results from the Balanced Evaluation of Atrial Tachyarrhythmias in Stimulated patients (BEATS) study. **2006**, 29, 582-8 26

903 Gains and losses of warfarin therapy as performed in an anticoagulation clinic. **2006**, 259, 296-304 24

902 Rapid achievement of therapeutic anticoagulation positively affects outcome in patients undergoing cardioversion for persistent atrial fibrillation. **2006**, 29, 78-82 4

901 What are the barriers to warfarin use in atrial fibrillation?: Development of a questionnaire. **2006**, 21, 257-65 31

900 [Anticoagulation with atrial fibrillation]. **2006**, 17, 89-94 1

899 Monitoring oral anticoagulants: new strategies for an emerging problem. **2006**, 1, 3-4 5

898 Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study. **2006**, 5, 749-54 126

897 Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen. **2006**, 77, 457-62 35

896 Long-term risk factors for stroke: twenty-eight years of follow-up of 7457 middle-aged men in G teborg, Sweden. **2006**, 37, 1663-7 97

895 Trends in risk of stroke in patients with a hospital diagnosis of nonvalvular atrial fibrillation: National Cohort Study in Denmark, 1980-2002. **2006**, 26, 212-9 30

894	Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. <b>2006</b> , 37, 1075-80	209
893	Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. <b>2006</b> , 27, 1947-53	83
892	Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). <b>2006</b> , 27, 1954-64	139
891	Potential new risk factors for ischemic stroke: what is their potential?. <b>2006</b> , 37, 2181-8	131
890	Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes	869
889	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive of Summary. <b>2006</b> , 114, 700-752-633	237
888	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial	479
887	Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. <b>2006</b> , 37, 447-51	224
886	Warfarin exposure and the risk of thromboembolic and major bleeding events among medicaid patients with atrial fibrillation. <b>2006</b> , 40, 1024-9	32
885	Anticoagulation management: a new approach. <b>2006</b> , 9, 201-9	13
884	ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). developed in	1653
883	collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. <b>2006</b> , 114, e257-354 Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. <b>2006</b> , 37, 1070-4	235
882	Influence of decision aids on patient preferences for anticoagulant therapy: a randomized trial. <b>2007</b> , 176, 1583-7	49
881	A patient decision aid to support shared decision-making on anti-thrombotic treatment of patients with atrial fibrillation: randomised controlled trial. <b>2007</b> , 16, 216-23	100
880	Challenges of establishing new antithrombotic therapies in atrial fibrillation. <b>2007</b> , 116, 449-55	74
879	Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. <b>2007</b> , 38, 874-80	59
878	Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?. <b>2007</b> , 38, 2459-63	59
877	A cautionary note on data sources for evidence-based clinical decisions: warfarin and stroke prevention. <b>2007</b> , 27, 438-47	2

876	Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. <b>2007</b> , 115, 2689-96	814
875	Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PROFESS). <b>2007</b> , 23, 368-80	145
874	Antiplatelets versus anticoagulation in cervical artery dissection. <b>2007</b> , 38, 2605-11	204
873	Angiotensin type 1 receptor blockade prevents endocardial dysfunction of rapidly paced atria in rats. <b>2007</b> , 8, 127-32	13
872	Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation. <b>2007</b> , 38, 624-30	99
871	Degree of anticoagulation, but not warfarin use itself, predicts adverse outcomes after traumatic brain injury in elderly trauma patients. <b>2007</b> , 63, 525-30	95
870	Pre-admission warfarin use in patients with acute ischemic stroke and atrial fibrillation: The appropriate use and barriers to oral anticoagulant therapy. <b>2007</b> , 120, 663-9	61
869	Antithrombotic therapy for prevention of stroke in clinical practice in the ED. <b>2007</b> , 25, 1-5	5
868	Delayed discharges due to initiation of warfarin in atrial fibrillation: a prospective audit. <b>2007</b> , 5, 232-5	7
867	Atherothrombotic ischemic stroke in patients with atrial fibrillation. <b>2007</b> , 109, 485-90	25
866	Home monitoring with a modified automatic sphygmomanometer to detect recurrent atrial fibrillation. <b>2007</b> , 16, 8-13	12
865	Anticoagulation clinics are needed in developing countries. <b>2007</b> , 115, 410-1	1
864	Primary prevention of dementia. <b>2007</b> , 3, 348-54	13
863	Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida. <b>2007</b> , 60, 525.e1-525.e64	7
862	Atrial fibrillation in the elderly. <b>2007</b> , 120, 481-7	57
861	The impact of warfarin use on clinical outcomes in atrial fibrillation: a population-based study. <b>2007</b> , 23, 457-61	24
860	Central Nervous System Ischemia. <b>2007</b> , 657-683	1
859	Modification of the Left Atrial Appendage. <b>2007</b> , 152-156	

858	Quelles pr�cautions chez un patient en arythmie compl�te par fibrillation auriculaire avant une anesth�sie ?. <b>2007</b> , 11, 290-300	
857	Management of warfarin in atrial fibrillation: views of health professionals, older patients and their carers. <b>2007</b> , 186, 175-80	40
856	Atrial fibrillation. <b>2007</b> , 186, 197-202	27
855	An emergency department diagnostic protocol for patients with transient ischemic attack: a randomized controlled trial. <b>2007</b> , 50, 109-19	87
854	Do physician outcome judgments and judgment biases contribute to inappropriate use of treatments? Study protocol. <b>2007</b> , 2, 18	11
853	Influence of age on the prescription of vitamin K antagonists in outpatients with permanent atrial fibrillation in France. <b>2007</b> , 16, 32-8	13
852	Stroke prevention in atrial fibrillation--things can only get better. <b>2007</b> , 64, 575-7	3
851	National underuse of anti-thrombotic therapy in chronic atrial fibrillation identified from digoxin prescribing. <b>2007</b> , 64, 706-9	14
850	Clinical pharmacology in the geriatric patient. <b>2007</b> , 21, 217-30	199
849	Stroke risk stratification in atrial fibrillation: something to EXAMINE more closely. <b>2007</b> , 61, 6-9	1
848	Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis. <b>2007</b> , 50, 421-32	40
847	Misuse of antithrombotic therapy in atrial fibrillation patients: frequent, pervasive and persistent. <b>2007</b> , 23, 65-71	23
846	Haemostatic genetic variants, ABO blood group and bleeding risk during oral anticoagulant treatment after cerebral ischaemia of arterial origin. <b>2007</b> , 254, 1660-5	7
845	Antiplatelet therapy for stroke prevention. <b>2007</b> , 9, 312-8	3
844	Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy. <b>2007</b> , 2, 24-8	32
843	New oral Xa and IIa inhibitors: updates on clinical trial results. <b>2008</b> , 25, 52-60	51
842	[Anticoagulation in atrial fibrillation - an update]. <b>2008</b> , 33, 556-60	0
841	Stroke unit care: recurrence, mortality and institutionalisation rates-a four year follow-up study. <b>2008</b> , 177, 135-9	3

840	Application of a decision support tool for anticoagulation in patients with non-valvular atrial fibrillation. <b>2008</b> , 23, 411-7	25
839	Kommentar zu âACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation âexecutive summaryâ2008, 2, 181-205	5
838	Patienten mit kardialen und zerebralen Durchblutungsst�ungen. <b>2008</b> , 2, 491-499	
837	Cardiovascular protection for all individuals at high risk: evidence-based best practice. <b>2008</b> , 97, 713-25	8
836	Stroke due to atrial fibrillation and the attitude to prescribing anticoagulant prevention in Italy. A prospective study of a consecutive stroke population admitted to a comprehensive stroke unit. <b>2008</b> , 255, 796-802	15
835	Examining warfarin underutilization rates in patients with atrial fibrillation: Detailed chart review essential to capture contraindications to warfarin therapy. <b>2008</b> , 6, 6	41
834	Prediction of hemorrhagic and thrombotic events in patients with mechanical heart valve prostheses treated with oral anticoagulants. <b>2008</b> , 6, 451-6	45
833	Wide variation in thrombin generation in patients with atrial fibrillation and therapeutic International Normalized Ratio is not due to inflammation. <b>2008</b> , 142, 946-52	36
832	Incidence of fatal adverse drug reactions: a population based study. <b>2008</b> , 65, 573-9	210
831	Medication persistence rates and factors associated with persistence in patients following stroke: a cohort study. <b>2008</b> , 8, 25	42
830	Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians' and patients' perspectives: protocol for a two-phase study. <b>2008</b> , 8, 221	32
829	Identifying the carotid 'high risk' plaque: is it still a riddle wrapped up in an enigma?. <b>2008</b> , 35, 2-8	39
828	The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <b>2008</b> , 133, 299S-339S	621
827	Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <b>2008</b> , 133, 257S-298S	549
826	Management of atrial fibrillation in heart failure in the elderly. <b>2008</b> , 125, 178-82	7
825	Economic Costs Associated with Atrial Fibrillation. <b>2008</b> , 13-26	4
824	Pharmacotherapy for atrial arrhythmias: present and future. <b>2008</b> , 5, S26-31	16
823	Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation. <b>2008</b> , 126, 316-21	48

822	Anticoagulant usage for primary stroke prevention: a general practitioner survey in local areas of metropolitan Sydney. <b>2008</b> , 15, 166-71	7
821	Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005. <b>2008</b> , 155, 829-40	14
820	The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon. <b>2008</b> , 123, 225-30	28
819	Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation--a nationwide descriptive study in Taiwan. <b>2008</b> , 30, 1726-36	119
818	[Atrial fibrillation in the elderly]. <b>2008</b> , 43, 106-12	5
817	Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. <b>2008</b> , 371, 315-21	217
816	Antithrombotic and thrombolytic therapy for ischemic stroke. <b>2008</b> , 26, 251-65, vii	5
815	Anticoagulation: stroke prevention in patients with atrial fibrillation. <b>2008</b> , 92, 143-59, xi	8
814	Stroke prevention in atrial fibrillation and other major cardiac sources of embolism. <b>2008</b> , 26, 1129-60, x-xi	25
813	Risk factor management to prevent first stroke. <b>2008</b> , 26, 1007-45, ix	39
812	Epidemiology and outcomes in patients with atrial fibrillation in the United States. <b>2008</b> , 5, 1365-72	56
811	Clinical and therapeutic aspects of vascular dementia. <b>2008</b> , 89, 659-70	
810	Reducing the risk for stroke in patients who have atrial fibrillation. <b>2008</b> , 26, 267-75, vii	13
809	Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. <b>2008</b> , 118, 2029-37	670
808	Will warfarin soon be pass? New approaches to stroke prevention in atrial fibrillation. <b>2008</b> , 52, 18-27	9
807	Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers. <b>2008</b> , 10, 395-402	19
806	The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. <b>2009</b> , 11, 423-34	263
805	Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians. <b>2008</b> , 39, 227-30	94



804	Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). <b>2008</b> , 39, 1482-6	130
803	Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <b>2008</b> , 133, 546S-592S	595
802	Antithrombotic treatment in atrial fibrillation. <b>2006</b> , 92, 155-61	31
801	Patient-specific decision-making for warfarin therapy in nonvalvular atrial fibrillation: how will screening with genetics and imaging help?. <b>2008</b> , 39, 3308-15	36
800	A novel endovascular device for emboli rerouting: part I: evaluation in a Swine model. <b>2008</b> , 39, 2860-6	9
799	Pharmacotherapy of atrial fibrillation: an old option with new possibilities. <b>2008</b> , 9, 913-25	4
798	Effect of ximelagatran and warfarin on stroke subtypes in atrial fibrillation. <b>2008</b> , 35, 160-5	1
797	Secondary stroke prevention: from guidelines to clinical practice. <b>2008</b> , 100, 1125-37	16
796	Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <b>2008</b> , 133, 160S-198S	1648
795	Soluble CD40 ligand, platelet surface CD40 ligand, and total platelet CD40 ligand in atrial fibrillation: relationship to soluble P-selectin, stroke risk factors, and risk factor intervention. <b>2008</b> , 134, 574-581	32
794	Radiofrequency Modified Maze Surgery for Chronic Atrial Fibrillation and Concomitant Cardiac Surgery: Zwolle Experience. <b>2008</b> , 143-153	
793	10 questions on atrial fibrillation. <b>2008</b> , 14, 390-4	1
792	Aggressive blood pressure control and stroke prevention: role of calcium channel blockers. <b>2008</b> , 26, 844-52	17
791	Role of anticoagulation therapy after pulmonary vein antrum isolation for atrial fibrillation treatment. <b>2008</b> , 9, 51-5	17
790	The pathophysiology and management of atrial fibrillation. <b>2008</b> , 3, 201-209	5
789	Cryptogenic stroke in a patient with a PFO: a decision analysis. <b>2008</b> , 335, 457-64	5
788	Anticoagulation and the elderly head trauma patient. <b>2008</b> , 74, 802-5	15
787	Prevention and treatment of cardioembolic stroke: a case study. <b>2009</b> , 24, 903-9	0

786	Cardioembolic stroke in atrial fibrillation-rationale for preventive closure of the left atrial appendage. <b>2009</b> , 39, 443-58	20
785	Epidemiology. 1-15	1
784	Risk factors. 16-29	
783	Pharmacological and electrical conversion of atrial fibrillation to sinus rhythm is worth the effort. <b>2009</b> , 120, 1436-43	24
782	Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. <b>2009</b> , 2, 429-36	84
781	Sleep apnea in stroke patients: hard to diagnose, even harder to treat. <b>2009</b> , 5, 193-205	
780	Warfarin: an inconvenient truth. <b>2009</b> , 40, 5-7	9
779	Substantial observer variability in the differentiation between primary intracerebral hemorrhage and hemorrhagic transformation of infarction on CT brain imaging. <b>2009</b> , 40, 3763-7	17
778	Contemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies. <b>2009</b> , 84, 643-62	51
777	Quality of life of elderly people on warfarin for atrial fibrillation. <b>2009</b> , 38, 751-4	8
776	Left atrial appendage occlusion does not eliminate the need for warfarin. <b>2009</b> , 120, 1927-32; discussion 1932	49
775	Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. <b>2009</b> , 119, e21-181	1705
774	[Stroke and atrial fibrillation]. <b>2009</b> , 20, 70-2	
773	[Antithrombotic therapy in atrial fibrillation: when vitamin K antagonists? When aspirin? When heparin? When combinations of anticoagulant and antiplatelet drugs?]. <b>2009</b> , 20, 61-9	
772	Indications of combined vitamin K antagonists and aspirin therapy. <b>2009</b> , 27, 421-9	1
771	Antikoagulation bei Vorhofflimmern âAltes und Neues. <b>2009</b> , 4, 176-183	0
770	Schlaganfallprvention versus Blutungsrisiko beim lteren Vorhofflimmernpatienten. <b>2009</b> , 4, 165-169	
769	Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation?. <b>2009</b> , 24, 543-9	7

768	[Prevention of stroke: what is evidence based?]. <b>2009</b> , 50, 1337-44	1
767	Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. <b>2009</b> , 28, 1861-81	169
766	Is primary care a neglected piece of the jigsaw in ensuring optimal stroke care? Results of a national study. <b>2009</b> , 10, 27	6
765	Clinical consequences of hospital variation in use of oral anticoagulant therapy after first-time admission for atrial fibrillation. <b>2009</b> , 265, 335-44	3
764	Searching for left atrial thrombi prior to catheter ablation of atrial fibrillation: are there patients who can safely avoid preablation transesophageal echocardiography?. <b>2009</b> , 20, 385-7	2
763	Warfarin is not needed in low-risk patients following atrial fibrillation ablation procedures. <b>2009</b> , 20, 988-93	62
762	Catheter ablation of atrial fibrillation in the elderly. <b>2009</b> , 32, 1085-91	18
761	Which is the optimal therapy to prevent thromboembolism after atrial fibrillation ablation procedures in low stroke risk patients, anticoagulation or antiplatelet therapy?. <b>2009</b> , 20, 994-6	3
760	Modelling the burden of stroke in Finland until 2030. <b>2009</b> , 4, 340-5	14
759	The costs of care in atrial fibrillation and the effect of treatment modalities in Germany. <b>2009</b> , 12, 293-301	40
758	Age and body weight adjusted warfarin initiation program for ischaemic stroke patients. <b>2009</b> , 16, 1100-5	12
757	Placental size and the prediction of severe early-onset intrauterine growth restriction in women with low pregnancy-associated plasma protein-A. <b>2009</b> , 34, 274-82	117
756	Predictors of stroke risk in native Chinese with nonrheumatic atrial fibrillation: retrospective investigation of hospitalized patients. <b>2009</b> , 32, 76-81	21
755	INR variability in atrial fibrillation: a risk model for cerebrovascular events. <b>2009</b> , 20, 63-9	23
754	A new era for anticoagulants. <b>2009</b> , 20, 562-8	39
753	[Indications of vitamin K antagonists and aspirin in the atrial fibrillation of the elderly]. <b>2009</b> , 30, 671-7	
752	The quality of anticoagulation on functional outcome and mortality for TIA/stroke in atrial fibrillation patients. <b>2009</b> , 132, 109-13	13
751	Perioperative management of acute ischemic stroke: a case report. <b>2009</b> , 21, 602-5	

750	Indirect comparison: relative risk fallacies and odds solution. <b>2009</b> , 62, 1031-6	29
749	Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. <b>2009</b> , 157, 1064-73	65
748	Antiplatelet therapy for the primary and secondary prevention of cerebrovascular events in patients with extracranial carotid artery disease. <b>2009</b> , 50, 431-9	10
747	Dabigatran versus warfarin in patients with atrial fibrillation. <b>2009</b> , 361, 1139-51	7909
746	Secondary stroke prevention strategies for the oldest patients: possibilities and challenges. <b>2009</b> , 26, 209-30	12
745	Combination of clopidogrel and aspirin for reduction of vascular events in patients with atrial fibrillation. <b>2009</b> , 7, 749-53	1
744	Treatment strategies to prevent stroke: focus on optimal lipid and blood pressure control. <b>2009</b> , 10, 955-66	3
743	Antithrombotic medication for stroke prevention. <b>2009</b> , 7, 1245-54	2
742	Manejo general y extrahospitalario del paciente con taquiarritmias. <b>2009</b> , 10, 2570-2578	
741	Contemporary Management of Atrial Fibrillation: Update on Anticoagulation and Invasive Management Strategies. <b>2009</b> , 84, 643-662	40
740	Milestones in the management of atrial fibrillation. <b>2009</b> , 6, S62-7	32
739	Atrial fibrillation in congestive heart failure: current management. <b>2009</b> , 27, 79-93, viii-ix	3
738	Update on medical management of atrial fibrillation in the modern era. <b>2009</b> , 6, S17-22	7
737	Anticoagulation: stroke prevention in patients with atrial fibrillation. <b>2009</b> , 27, 125-35, ix	5
736	The current role of anticoagulants in cardiovascular medicine. <b>2009</b> , 10, 595-604	13
735	The need for new oral anticoagulants in clinical practice. <b>2009</b> , 10, 605-9	15
734	Pulse check as a screen for atrial fibrillation. <b>2009</b> , 20, 310-313	4
733	Hyperhomocysteinemia as an independent risk factor for cardioembolic stroke in the Turkish population. <b>2009</b> , 218, 293-300	11

732	Pulse check as a screen for atrial fibrillation. <b>2009</b> , 4, 426-429	
731	Percutaneous closure of the left atrial appendage in atrial fibrillation: an alternative if standard treatment fails?. <b>2009</b> , 1, 119-131	
730	Assessment of left atrial appendage function with transthoracic tissue Doppler echocardiography. <b>2009</b> , 10, 363-71	44
729	Rivaroxaban, a new oral factor Xa inhibitor, provides new data on anticoagulation. <b>2009</b> , 6, 187-189	1
728	Anticoagulation therapy for cardioembolic stroke prevention in the elderly: defining benefits and risks. <b>2010</b> , 6, 439-450	2
727	Update on antithrombotic therapy for stroke prevention in atrial fibrillation. <b>2010</b> , 12, 250-60	1
726	Atrial Fibrillation in the Elderly. <b>2010</b> , 4, 354-360	
725	Gleichzeitige Anwendung von Thrombozytenaggregationshemmern und Protonenpumpeninhibitoren (PPIs). <b>2010</b> , 4, 353-364	1
724	Left atrial appendage closure. <b>2010</b> , 12, 413-21	23
723	Combined oral anticoagulants and antiplatelets: benefits and risks. <b>2010</b> , 5, 281-90	14
722	The risk of myocardial infarction in patients with atrial fibrillation: an unresolved issue. <b>2010</b> , 5, 91-4	19
721	Antiplatelet therapy in secondary stroke prevention--state of the art. <b>2010</b> , 14, 2552-60	8
720	Oral anticoagulation in elderly patients as secondary prevention of cardioembolic strokes. <b>2010</b> , 3, 8	6
719	Japanese guidelines for the management of stroke (2009) :. <b>2010</b> , 21, 371-377	
718	Update on Rivaroxaban. <b>2010</b> , 3, CMBD.S5101	
717	Relationship between CHADS2 score and ischemic stroke during rhythm control therapy for paroxysmal atrial fibrillation. <b>2010</b> , 51, 24-9	12
716	Determining patient characteristics for decision analysis support systems using anonymized electronic patient records. <b>2010</b> , 16, 49-57	2
715	Getting a Better Grip on Research: The Maze of the Most Busy Life. <b>2010</b> , 3, 172-179	4

714	Emergency reversal of anticoagulation and antiplatelet therapies in neurosurgical patients. <b>2010</b> , 112, 307-18	67
713	Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. <b>2010</b> , 31, 967-75	254
712	Will direct thrombin inhibition change the boundaries of oral anti-coagulation?. <b>2010</b> , 103, 429-34	2
711	Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors. <b>2010</b> , 26, 1023-30	30
710	Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature. <b>2010</b> , 44, 851-62	16
709	Adverse events associated with anticoagulation therapy in the periendoscopic period. <b>2010</b> , 71, 1211-1217.e2	31
708	Prevention of stroke by percutaneous left atrial appendage closure: short term follow-up. <b>2010</b> , 142, 195-6	12
707	Survival after stroke--the impact of CHADS2 score and atrial fibrillation. <b>2010</b> , 141, 18-23	98
706	Antithrombotic treatment for the primary prevention of stroke in patients with non valvular atrial fibrillation: a reappraisal of the evidence and network meta analysis. <b>2010</b> , 142, 218-23	9
705	Stroke in heart failure: atrial fibrillation revisited?. <b>2010</b> , 19, 1-2	22
704	[Atrial fibrillation: who should be anticoagulated?]. <b>2010</b> , 39, 669-81	
703	Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. <b>2010</b> , 21, 516-23	44
702	The science of stroke: mechanisms in search of treatments. <b>2010</b> , 67, 181-98	1329
701	Small intestinal bacterial overgrowth and warfarin dose requirement variability. <b>2010</b> , 126, 12-7	19
700	Apixaban for reduction in stroke and other Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. <b>2010</b> , 159, 331-9	345
699	Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. <b>2010</b> , 159, 348-353.e1	118
698	Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. <b>2010</b> , 159, 340-347.e1	337
697	Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). <b>2010</b> , 160, 635-41	377

696	Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. <b>2010</b> , 123, 134-40	35
695	Are atrial fibrillation patients receiving warfarin in accordance with stroke risk?. <b>2010</b> , 123, 446-53	120
694	Heart disease and stroke statistics--2010 update: a report from the American Heart Association. <b>2010</b> , 121, e46-e215	3147
693	New antithrombotics for atrial fibrillation. <b>2010</b> , 28, 278-86	12
692	Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?. <b>2010</b> , 28, 295-301	7
691	Surgical workload, risk factors and complications in patients on warfarin with gastrointestinal bleeding. <b>2010</b> , 8, 52-5	4
690	Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation. <b>2010</b> , 126, e69-77	30
689	Contemporary management of atrial fibrillation: a brief review. <b>2010</b> , 55, 130-6	2
688	Tratamiento de las taquiarritmias postoperatorias en la cirugía cardíaca del adulto. <b>2010</b> , 17, 275-282	
687	Could geriatric characteristics explain the under-prescription of anticoagulation therapy for older patients admitted with atrial fibrillation? A retrospective observational study. <b>2010</b> , 27, 807-13	36
686	Predictors of warfarin use in atrial fibrillation patients in the inpatient setting. <b>2010</b> , 10, 37-48	38
685	Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation. <b>2011</b> , 11, 265-75	11
684	Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. <b>2011</b> , 9, 279-86	14
683	2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Association. <b>2011</b> , 57, 223-42	645
682	Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. <b>2011</b> , 57, 831-8	267
681	2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <b>2011</b> , 57, 223-42	224
680	Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. <b>2011</b> , 365, 883-91	6302
679	Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. <b>2011</b> , 105, 908-19	154

678	How valuable are multiple treatment comparison methods in evidence-based health-care evaluation?. <b>2011</b> , 14, 371-80	48
677	Heart disease and stroke statistics--2011 update: a report from the American Heart Association. <b>2011</b> , 123, e18-e209	3795
676	2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <b>2011</b> , 8, 157-76	100
675	Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. <b>2011</b> , 161, 241-6	83
674	The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: data from the Heart and Soul Study. <b>2011</b> , 162, 555-61	78
673	Canadian Cardiovascular Society atrial fibrillation guidelines 2010: etiology and initial investigations. <b>2011</b> , 27, 31-7	54
672	Apixaban versus warfarin in patients with atrial fibrillation. <b>2011</b> , 365, 981-92	5856
671	Platelet activation and induction of tissue factor in acute and chronic atrial fibrillation: involvement of mononuclear cell-platelet interaction. <b>2011</b> , 128, e113-8	36
670	[Efficiency of acute geriatric units: a meta-analysis of controlled studies]. <b>2011</b> , 46, 186-92	7
669	The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation. <b>2011</b> , 7, 193-202	31
668	Antithrombotic medication for cardioembolic stroke prevention. <b>2011</b> , 2011, 607852	11
667	Impact of the type of centre on management of AF patients: surprising evidence for differences in antithrombotic therapy decisions. <b>2011</b> , 105, 1010-23	56
666	The perils of combination antithrombotic therapy and potential resolutions. <b>2011</b> , 42, 278-81	6
665	Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation. <b>2011</b> , 26, 294-9	4
664	Current and emerging therapies for stroke prophylaxis in atrial fibrillation. <b>2011</b> , 1, 1019-1037	
663	Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation. - A multicenter study of its status and influential factors-. <b>2011</b> , 75, 2087-94	43
662	[Pharmacological and clinical profiles of the direct thrombin inhibitor dabigatran etexilate methane sulfatate (Praxa(®))]. <b>2011</b> , 138, 79-88	0
661	A retrospective study to assess the morbidity associated with transurethral prostatectomy in patients on antiplatelet or anticoagulant drugs. <b>2011</b> , 108 Suppl 2, 45-50	35



660	Stroke risk assessment for atrial fibrillation: hospital-based stroke risk assessment and intervention program. <b>2011</b> , 36, 71-9	6
659	Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification. <b>2011</b> , 9, 441-9	26
658	The Society of Thoracic Surgeons practice guideline on the prophylaxis and management of atrial fibrillation associated with general thoracic surgery: executive summary. <b>2011</b> , 92, 1144-52	84
657	Prolonged rhythm monitoring for the detection of occult paroxysmal atrial fibrillation in ischemic stroke of unknown cause. <b>2011</b> , 124, 477-86	204
656	Prévention secondaire des infarctus cérébraux liés à l'arythmie complète par fibrillation auriculaire : quel(s) traitement(s) et dans quel(s) délai(s) ?. <b>2011</b> , 2, 6-20	
655	Stroke Genetics Update: 2011. <b>2011</b> , 5, 533-541	7
654	Prevention of cardioembolic stroke. <b>2011</b> , 8, 488-502	21
653	[Anticoagulation in atrial fibrillation. Strategies in special situations]. <b>2011</b> , 6, 58-65	
652	The determinants of stroke phenotypes were different from the predictors (CHADS2 and CHA2DS2-VASc) of stroke in patients with atrial fibrillation: a comprehensive approach. <b>2011</b> , 11, 107	3
651	Pitfalls in meta-analyses on adverse events reported from clinical trials. <b>2011</b> , 20, 1014-20	18
650	Triple therapy in hospitalized patients: facts and controversies. <b>2011</b> , 6, 537-45	1
649	Atrial fibrillation in the aging heart: pharmacological therapy and catheter ablation in the elderly. <b>2011</b> , 7, 415-23	4
648	Advances in genetics 2010. <b>2011</b> , 42, 285-7	5
647	Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. <b>2011</b> , 4, 14-21	179
646	Atrial fibrillation. Left atrial fibrosis--a promising stroke risk factor?. <b>2011</b> , 8, 307-8	7
645	Patent foramen ovale: anatomy, outcomes, and closure. <b>2011</b> , 8, 148-60	110
644	Does catheter ablation eliminate the need for oral anticoagulation?. <b>2011</b> , 4, 595-7	1
643	The ABCD and ABCD2 Scores and the Risk of Stroke following a TIA: A Narrative Review. <b>2011</b> , 2011, 518621	6

642	2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <b>2011</b> , 123, 104-23	298
641	2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <b>2011</b> , 123, e269-367	643
640	The perils of combination antithrombotic therapy and potential resolutions. <b>2011</b> , 123, 232-5	10
639	Challenges of stroke prevention in patients with atrial fibrillation in clinical practice. <b>2011</b> , 104, 739-46	7
638	Observational process-outcome associations for real-world ambulatory heart failure care: moving toward clarity, or clouding the view?. <b>2011</b> , 123, 1581-3	1
637	Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. <b>2011</b> , 91, 265-325	785
636	Management of patients with atrial fibrillation: specific considerations for the old age. <b>2011</b> , 2011, 854205	2
635	Safety and efficacy of apixaban in the treatment of atrial fibrillation. <b>2012</b> , 6, 103-9	1
634	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <b>2012</b> , 33, 1787-847	3691
633	A guidance pathway for the selection of novel anticoagulants in the treatment of atrial fibrillation. <b>2012</b> , 11, 55-61	3
632	Perceived or actual barriers to warfarin use in atrial fibrillation based on electronic medical records. <b>2012</b> , 19, 330-7	22
631	Newer anticoagulants in cardiovascular disease: a systematic review of the literature. <b>2012</b> , 20, 209-21	21
630	Minimally invasive surgical implantation of the percutaneous left atrial appendage transcatheter occlusion device: initial experience in a canine model. <b>2012</b> , 7, 52-8	
629	Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation. <b>2012</b> , 11, 45-54	1
628	Providing best practice in the management of atrial fibrillation in the United States. <b>2012</b> , 27, 445-56	8
627	Does catheter ablation for atrial fibrillation increase or reduce neurological insult?. <b>2012</b> , 27, 36-40	2
626	Dabigatran: comparison to warfarin, pathway to approval, and practical guidelines for use. <b>2012</b> , 17, 237-47	4
625	Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. <b>2012</b> , 105, 949-57	36

624	Neurosurgical complications of direct thrombin inhibitors--catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. <b>2012</b> , 116, 1093-6	79
623	Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians. <b>2012</b> , 91, 777-86	6
622	¿Es posible prevenir la fibrilacion auricular y sus complicaciones?. <b>2012</b> , 23, 732-741	
621	Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark. <b>2012</b> , 15, 695-703	43
620	New anticoagulants in atrial fibrillation: an update for clinicians. <b>2012</b> , 3, 37-45	6
619	Stroke Prevention in Atrial Fibrillation: Where are We Now?. <b>2012</b> , 6, 65-78	8
618	Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <b>2012</b> , 141, e326S-e350S	1175
617	Mechanism of ischemic infarct in spontaneous cervical artery dissection. <b>2012</b> , 43, 1354-61	58
616	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETWORK/European Heart Rhythm Association consensus conference. <b>2012</b> , 14, 8-27	156
615	Evidence-based percutaneous closure of the left atrial appendage in patients with atrial fibrillation. <b>2012</b> , 8, 37-42	8
614	Stroke prevention in atrial fibrillation: concepts and controversies. <b>2012</b> , 8, 290-301	8
613	Anatomical and visual results of transconjunctival sutureless vitrectomy using subconjunctival anesthesia performed on select patients taking anticoagulant and antiplatelet agents. <b>2012</b> , 32, 905-11	12
612	First in vivo use of a capacitive micromachined ultrasound transducer array-based imaging and ablation catheter. <b>2012</b> , 31, 247-56	23
611	Stroke risk assessment in atrial fibrillation. <b>2012</b> , 10-29	1
610	Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. <b>2012</b> , 14, 1553-9	117
609	A new era of antithrombotic therapy in patients with atrial fibrillation. <b>2012</b> , 344, 128-35	2
608	Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. <b>2012</b> , 10, 1979-87	24
607	[Rivaroxaban in the prevention and treatment of thromboembolic disorders]. <b>2012</b> , 32, 195-202	

606	Atrial Fibrillation: Focus on Anticoagulant Pharmacotherapy. <b>2012</b> , 8, 560-565	0
605	A novel carotid device for embolic diversion: lessons learned from a "first in man" trial in patients with atrial fibrillation. <b>2012</b> , 35, 406-12	2
604	Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong. <b>2012</b> , 35, E40-5	28
603	Management of atrial fibrillation: direct factor IIa and Xa inhibitors or "warfarin shotgun"?. <b>2012</b> , 79, 705-20	1
602	Diagnosis and management of atrial fibrillation by primary care physicians in Italy : a retrospective, observational analysis. <b>2012</b> , 32, 771-7	6
601	Les nouveaux anticoagulants. <b>2012</b> , 73, 344-345	
600	High rate of anticoagulation therapy in oldest old subjects with atrial fibrillation: the Octabaix study. <b>2012</b> , 13, 8-10	9
599	Prophylaxis and management of atrial fibrillation after general thoracic surgery. <b>2012</b> , 22, 13-23, v	16
598	[Anticoagulation and atrial fibrillation]. <b>2012</b> , 43, 308-12	
597	Data and Safety Monitoring. <b>2012</b> , 101-108	
596	Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. <b>2012</b> , 5, 711-9	87
595	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <b>2012</b> , 11, 808-10	1892
594	Fibrilaci3 auricular: una mirada actual. <b>2012</b> , 19, 235-251	2
593	Use of anticoagulants in elderly patients. <b>2012</b> , 129, 107-15	42
592	Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation. <b>2012</b> , 129, 9-16	7
591	Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature. <b>2012</b> , 129, 392-400	49
590	Warfarin use in nursing home residents: results from the 2004 national nursing home survey. <b>2012</b> , 10, 25-36.e2	18
589	New drugs for thromboprophylaxis in atrial fibrillation. <b>2012</b> , 23, 1-5	13

588	Effects of computer-assisted oral anticoagulant therapy. <b>2012</b> , 10, 17	8
587	Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation. <b>2012</b> , 9, 385-91	13
586	Temporal trends in ischemic and hemorrhagic strokes in Northern Italy: results from the cardiovascular monitoring unit in Northern Italy population-based register, 1998-2004. <b>2012</b> , 39, 35-42	3
585	Relation of gender-specific risk of ischemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control (from AFFIRM). <b>2012</b> , 110, 1799-802	71
584	Caregiver assistance among Medicare beneficiaries with atrial fibrillation and factors associated with anticoagulant treatment. <b>2012</b> , 10, 273-83	4
583	Left atrial appendage occlusion for stroke prevention. <b>2012</b> , 37, 405-41	16
582	Percutaneous exclusion of the left atrial appendage in prevention of systemic embolism. <b>2012</b> , 54, e156-e161	1
581	Assessment of advantages and disadvantages of agents used for therapeutic anticoagulation. <b>2012</b> , 58, 462-8	
580	Clinical outcome of stable outpatients with coronary, cerebrovascular or peripheral artery disease, and atrial fibrillation. <b>2012</b> , 130, 390-5	29
579	Anticoagulants. <b>2012</b> , 357-362	
578	Antithrombotic treatment of atrial fibrillation: new insights. <b>2012</b> , 130 Suppl 1, S59-60	7
577	Atrial fibrillation in heart failure. <b>2012</b> , 9, 309-18	7
576	Left atrial strain is reduced in patients with atrial fibrillation, stroke or TIA, and low risk CHADS(2) scores. <b>2012</b> , 25, 1327-32	65
575	Nuevos tratamientos anticoagulantes para la prevención del ictus y la embolia sistémica en la fibrilación auricular no valvular. <b>2012</b> , 12, 11-17	1
574	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. <b>2012</b> , 65, 938.e1-938.e59	27
573	Anticoagulation therapy for patients with non-valvular atrial fibrillation: comparison of decision analytic model recommendations and real-world warfarin prescription use. <b>2012</b> , 12, 313-23	20
572	Anticoagulant and antiplatelet therapy in patients with atrial fibrillation and coronary artery disease. <b>2012</b> , 2012, 184573	4
571	Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin?. <b>2012</b> , 27, 445-52	1

570	An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation. <b>2012</b> , 7, 49-59	10
569	Warfarin and aspirin in patients with heart failure and sinus rhythm. <b>2012</b> , 366, 1859-69	416
568	Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <b>2012</b> , 141, e44S-e88S	1112
567	Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <b>2012</b> , 141, e531S-e575S	763
566	Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <b>2012</b> , 141, e152S-e184S	920
565	Anticoagulation-related intracranial hemorrhages. <b>2012</b> , 14, 351-9	16
564	Kann die Indikation zur Antikoagulation durch die Katheterablation von Vorhofflimmern ersetzt werden?. <b>2012</b> , 6, 226-231	
563	Management of postoperative atrial fibrillation. <b>2012</b> , 26, 429-37	38
562	New anticoagulants for the prevention of stroke in atrial fibrillation. <b>2012</b> , 26, 47-53	6
561	Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. <b>2012</b> , 11, 503-11	212
560	Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part D. <b>2012</b> , 59, 670-81	24
559	Catheter ablation of atrial fibrillation in octogenarians: safety and outcomes. <b>2012</b> , 23, 687-93	90
558	Development of a Computerised Antithrombotic Risk Assessment Tool (CARAT) to optimise therapy in older persons with atrial fibrillation. <b>2012</b> , 31, 102-9	13
557	The economics of atrial fibrillation: a time for review and prioritization. <b>2012</b> , 7, 477-9	7
556	The health care setting rather than medical speciality impacts on physicians adherence to guideline-conform anticoagulation in outpatients with non-valvular atrial fibrillation: a cross sectional survey. <b>2012</b> , 12, 12	5
555	Promise of factor Xa inhibition in atrial fibrillation. <b>2012</b> , 14, 70-8	2
554	Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment. <b>2012</b> , 16, 203-9	30
553	Kommentar zu den Leitlinien der ESC zum Vorhofflimmern. <b>2012</b> , 6, 12-27	7

552	Supraventricular and ventricular arrhythmias. <b>2013</b> , 40, 43-71	4
551	Atrial Fibrillation and Race - A Contemporary Review. <b>2013</b> , 7, 336	36
550	[Patient selection for the implantation of a left atrial appendage occluder in primary and secondary prevention of cardioembolic stroke in atrial fibrillation]. <b>2013</b> , 24, 25-32	
549	Stroke Prevention in Atrial Fibrillation. <b>2013</b> , 1, 98-104	
548	Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry. <b>2013</b> , 61, 260-6	159
547	Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. <b>2013</b> , 62, 108-118	314
546	Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). <b>2013</b> , 61, 651-8	159
545	La fibrillation atriale chez la personne âgée : actualités de la prise en charge thérapeutique selon les dernières recommandations (2012) de la Société européenne de cardiologie : focus sur le traitement anticoagulant. <b>2013</b> , 5, 245-256	1
544	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). <b>2013</b> , 34, 3035-87	1444
543	Ischemic stroke in patients with atrial fibrillation receiving oral anticoagulation. <b>2013</b> , 334, 139-42	12
542	Atrial Fibrillation and Flutter: Diagnosis and Treatment. <b>2013</b> , 85-100	
541	Cardiovascular pharmacology core reviews: aspirin. <b>2013</b> , 18, 505-13	8
540	Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. <b>2013</b> , 35, 967-984.e2	33
539	[New anticoagulants in patients with atrial fibrillation]. <b>2013</b> , 155, 55-6, 58	
538	More outcomes than trials: a call for consistent data collection across stroke rehabilitation trials. <b>2013</b> , 8, 18-24	32
537	Eficacia comparativa y costo-eficacia de los nuevos anticoagulantes orales para prevención de accidente cerebrovascular en pacientes con fibrilación auricular no valvular. <b>2013</b> , 5, 228-232	
536	Warfarin, acetylsalicylic acid and risk of incident atrial fibrillation in patients with heart failure and sinus rhythm: a meta-analysis. <b>2013</b> , 168, 4842-3	
535	Prolonged Rhythm Monitoring in the Patient with Stroke and Transient Ischemic Attack. <b>2013</b> , 5, 349-356	

534	Does chronic warfarin cause increased blood loss and transfusion during lumbar spinal surgery?. <b>2013</b> , 13, 1253-8	11
533	Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study. <b>2013</b> , 24, 318-23	20
532	Spontaneous cervical and cerebral arterial dissections: diagnosis and management. <b>2013</b> , 23, 661-71	29
531	Trifecta or triple threat? The challenge of post-PCI management in patients receiving chronic oral anticoagulant therapy. <b>2013</b> , 29, 136-8	2
530	Temporal trends in medication use and outcomes in atrial fibrillation. <b>2013</b> , 29, 1241-8	30
529	Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting. <b>2013</b> , 46, 45-50	18
528	Dose-adjusted warfarin: writing the prescription is only the beginning. <b>2013</b> , 46, 51-3	
527	[Improvements in oral anticoagulant therapy for atrial fibrillation]. <b>2013</b> , 141, 487-93	2
526	Central Nervous System Ischemia. <b>2013</b> , 669-697	
525	Atrial fibrosis: a risk stratifier for atrial fibrillation. <b>2013</b> , 11, 155-60	14
524	Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions. <b>2013</b> , 1291, 42-55	16
523	Novel oral anticoagulants in gastroenterology practice. <b>2013</b> , 78, 227-39	71
522	Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. <b>2013</b> , 8, e62183	44
521	Review of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the US. <b>2013</b> , 47, 671-85	5
520	Pharmacokinetic considerations for antithrombotic therapies in stroke. <b>2013</b> , 9, 1335-47	4
519	Acute Ischaemic Stroke Agnieszka Anna Ardelt. <b>2013</b> , 655-735	
518	We ignore confidence intervals at our peril. <b>2013</b> , 74, 707	
517	Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. <b>2013</b> , 44, 3103-8	214



516	Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012. <b>2013</b> , 125, 146-57		
515	Novel anticoagulants for stroke prevention in atrial fibrillation among diabetics. <b>2013</b> , 13, 51-55		1
514	Comparison of Atrial Fibrillation in the Young versus That in the Elderly: A Review. <b>2013</b> , 2013, 976976		36
513	The unappreciated importance of blood pressure in recent and older atrial fibrillation trials. <b>2013</b> , 31, 2109-17; discussion 2117		14
512	A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. <i>Journal of the American Heart Association</i> , <b>2013</b> , 2, e000250	6	225
511	Evaluation and management of the atrial fibrillation patient: a report from the Society of Cardiovascular Patient Care. <b>2013</b> , 12, 107-15		4
510	Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial. <b>2013</b> , 36, 74-8		5
509	Updated meta-analysis on antithrombotic therapy in patients with heart failure and sinus rhythm. <b>2013</b> , 15, 69-78		25
508	Will One Size of Anticoagulant Dosage Fit All?. <b>2013</b> , 74, 406-412		2
507	Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. <b>2013</b> , 34, 177-83		48
506	Does warfarin use impact hospital length of stay? A retrospective study looking at patients treated for atrial fibrillation. <b>2013</b> , 91, 20-4		3
505	Role of imaging in interventions on structural heart disease. <b>2013</b> , 11, 1659-76		10
504	Overview of pathophysiology and management of AF. <b>2013</b> , 8, 241-249		5
503	Vitamin K antagonists in patients with nonvalvular atrial fibrillation: appropriateness and quality of treatment in an Italian cohort. <b>2013</b> , 14, 534-40		7
502	Treatment patterns associated with stroke prevention in patients with atrial fibrillation in three major cities in the People's Republic of china. <b>2013</b> , 7, 29-35		1
501	Analysis of antithrombotic therapy after cardioembolic stroke due to atrial fibrillation or flutter. <b>2013</b> , 48, 127-33		
500	Management of cardiac arrhythmias. <b>2014</b> , 200-259.e4		0
499	Characteristics of pulmonary vein enlargement in non-valvular atrial fibrillation patients with stroke. <b>2014</b> , 55, 1516-25		

498	Intracranial haemorrhage: therapeutic interventions and anaesthetic management. <b>2014</b> , 113 Suppl 2, ii17-25	10
497	Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders. <b>2014</b> , 4, 619-639	1
496	Prevention of Stroke in Patients With Atrial Fibrillation. <b>2014</b> , 1129-1137	
495	Evaluation of the WATCHMAN left atrial appendage closure device. <b>2014</b> , 11, 541-51	5
494	Shared decision making in atrial fibrillation: where we are and where we should be going. <b>2014</b> , 129, 704-10	73
493	Neurologic Manifestations of Acquired Cardiac Disease, Arrhythmias, and Interventional Cardiology. <b>2014</b> , 79-97	
492	Pathways to poor anticoagulation control. <b>2014</b> , 12, 628-34	22
491	Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study. <b>2014</b> , 12, 824-30	9
490	Sharpen your pencils: implications of recognizing atrial fibrillation after stroke. <b>2014</b> , 21, 1-2	1
489	Advantages and limitations of the new anticoagulants. <b>2014</b> , 275, 1-11	61
488	Safety of percutaneous left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation and contraindications to anticoagulation. <b>2014</b> , 83, 796-802	16
487	Qualit� della terapia con dicumarolici, nuovi anticoagulanti orali, e ruolo dei centri per la terapia anticoagulante. <b>2014</b> , 10, 204-211	
486	Risk factors of stroke in Western and Asian countries: a systematic review and meta-analysis of prospective cohort studies. <b>2014</b> , 14, 776	36
485	ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary. <b>2014</b> , 11, 133-73	137
484	EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. <b>2014</b> , 16, 1397-416	185
483	Get With The Guidelines AFIB: novel quality improvement registry for hospitalized patients with atrial fibrillation. <b>2014</b> , 7, 770-7	36
482	Silent atrial fibrillation after ischemic stroke or transient ischemic attack: interest of continuous ECG monitoring. <b>2014</b> , 71, 313-8	7
481	2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. <b>2014</b> , 130, e199-267	1016

480	Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation. <b>2014</b> , 1329, 93-106	18
479	Anticoagulant and antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. <b>2014</b> , 114, 70-8	46
478	Adherence and persistence in the use of warfarin after hospital discharge among patients with heart failure and atrial fibrillation. <b>2014</b> , 20, 23-30	17
477	Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure. <b>2014</b> , 19, 391-401	10
476	Warfarin and atrial fibrillation: from ideal to real the warfarin affaire. <b>2014</b> , 12, 5	26
475	[Oral anticoagulation for atrial fibrillation]. <b>2014</b> , 25, 3-11	
474	Evidence behind quality of care measures for venous thromboembolism and atrial fibrillation. <b>2014</b> , 37, 87-96	4
473	Optimizing antithrombotic therapy after coronary stent implantation in patients on chronic oral anticoagulation. <b>2014</b> , 7, 64-71	2
472	Patients satisfaction with warfarin and willingness to switch to dabigatran: a patient survey. <b>2014</b> , 38, 115-20	17
471	2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <b>2014</b> , 64, e1-76	2768
470	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. <b>2014</b> , 67, 136.e1-136.e56	8
469	The current status of bridging anticoagulation. <b>2014</b> , 164, 619-29	14
468	Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications. <b>2014</b> , 43, 48-59	19
467	Left atrial appendage occlusion: opportunities and challenges. <b>2014</b> , 63, 291-8	53
466	The economic burden to medicare of stroke events in atrial fibrillation populations with and without thromboprophylaxis. <b>2014</b> , 17, 159-65	7
465	Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial. <b>2014</b> , 38, 176-81	17
464	Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. <b>2014</b> , 35, 224-32	118
463	Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation. <b>2014</b> , 22, 252-8	17

462	Cost-effectiveness of early detection of atrial fibrillation via remote control of implanted devices. <b>2014</b> , 20, 570-7	13
461	Reply: Left atrial appendage occlusion devices versus pharmacological agents for stroke prevention in atrial fibrillation: testing the noninferiority margins. <b>2014</b> , 7, 943	2
460	Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches?. <i>Journal of the American Heart Association</i> , <b>2014</b> , 3, 6	33
459	Beyond warfarin: a patient-centered approach to selecting novel oral anticoagulants for stroke prevention in atrial fibrillation. <b>2014</b> , 9, 400-6	9
458	Oral anticoagulant use in patients with chronic kidney disease: how to choose, and the importance of empiric human data. <b>2014</b> , 30, 853-4	2
457	Prolonged cardiac monitoring for detection of paroxysmal atrial fibrillation after cerebral ischemia. <b>2014</b> , 45, 1208-14	21
456	[Direct anticoagulants for atrial fibrillation. Update 2014]. <b>2014</b> , 39, 357-67; quiz 368	2
455	Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. <b>2014</b> , 40, 277-84	38
454	Adherence to guidelines and mortality in atrial fibrillation. <b>2014</b> , 176, 430-6	13
453	Anti-thrombotic therapy in patients with atrial fibrillation and intracranial hemorrhage. <b>2014</b> , 14, 1019-28	11
452	Leaving no hole unclosed: left atrial appendage occlusion in patients having closure of patent foramen ovale or atrial septal defect. <b>2014</b> , 27, 414-22	13
451	Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. <b>2014</b> , 168, 160-7	53
450	The role of multimodality imaging in percutaneous left atrial appendage suture ligation with the LARIAT device. <b>2014</b> , 27, 699-708	15
449	Mechanical closure devices for atrial fibrillation. <b>2014</b> , 24, 225-31	2
448	Inappropriate use of oral anticoagulants for patients with atrial fibrillation. <b>2014</b> , 78, 2166-72	102
447	Risk-treatment paradox of anticoagulation therapy in atrial fibrillation. <b>2014</b> , 78, 2146-8	
446	Effects of anticoagulant and antiplatelet drugs on the risk for hospital admission for traumatic injuries: a case-control and population-based study. <b>2014</b> , 76, 437-42	13
445	Use of drug-eluting versus bare-metal stents after an acute coronary syndrome in Portugal: The EURHOBOP study. <b>2015</b> , 34, 449-456	3

444	Improving anticoagulation uptake within primary care. <b>2015</b> , 10, 175-178	2
443	Vorhofflimmern: orale Antikoagulation. <b>2015</b> , 15, 52-56	
442	Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysis. <b>2015</b> , 15, 104	3
441	Warfarin usage among elderly atrial fibrillation patients with traumatic injury, an analysis of United States Medicare fee-for-service enrollees. <b>2015</b> , 55, 25-32	3
440	Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation. <b>2015</b> , 33, 177-83	48
439	Why Is Left Atrial Appendage Morphology Related to Strokes? An Analysis of the Flow Velocity and Orifice Size of the Left Atrial Appendage. <b>2015</b> , 26, 922-927	44
438	The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society. <b>2015</b> , 45, 9-19	33
437	Kidney and haemostasis. A (personal) time-journey. <b>2015</b> , 35, 73-6	1
436	Left Atrial Appendage: Physiology, Pathology, and Role as a Therapeutic Target. <b>2015</b> , 2015, 205013	40
435	Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial. <b>2015</b> , 13, 699-707	38
434	Strategies to incorporate left atrial appendage occlusion into clinical practice. <b>2015</b> , 65, 2337-44	7
433	Comparison between CHA2DS2-VASc and the new R2CHADS2 and ATRIA scores at predicting thromboembolic event in non-anticoagulated and anticoagulated patients with non-valvular atrial fibrillation. <b>2015</b> , 15, 156	19
432	Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience. <b>2015</b> , 8, 1925-1932	61
431	Stroke Event Rates and the Optimal Antithrombotic Choice of Patients With Paroxysmal Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <b>2015</b> , 94, e2364	2
430	From decision to shared-decision: Introducing patients' preferences into clinical decision analysis. <b>2015</b> , 65, 19-28	21
429	Pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban after oral and intravenous administration to cats. <b>2015</b> , 76, 732-8	9
428	Primary Care Atrial Fibrillation Service: outcomes from consultant-led anticoagulation assessment clinics in the primary care setting in the UK. <b>2015</b> , 5, e009267	14
427	Left Atrial Appendage Ligation in Nonvalvular Atrial Fibrillation Patients at High Risk for Embolic Events With Ineligibility for Oral Anticoagulation: Initial Report of Clinical Outcomes. <b>2015</b> , 1, 465-474	26

426	Direct factor Xa inhibitor edoxaban: from bench to clinical practice. <b>2015</b> , 8, 707-25	1
425	Vitamin K Antagonists (Coumarins), Drugs Used in the Prevention and Treatment of Cardioembolism, Deep Vein Thrombosis, and Pulmonary Embolism. <b>2015</b> , 395-398	1
424	Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. <b>2015</b> , 36, 297-306	108
423	Dementia in patients with atrial fibrillation and the value of the Hachinski ischemic score. <b>2015</b> , 15, 770-7	19
422	Stroke prevention--medical and lifestyle measures. <b>2015</b> , 73, 150-7	56
421	Warfarin therapy for atrial fibrillation in haemodialysis patients: mind the (evidence) gap. <b>2015</b> , 30, 337-9	3
420	Graphical representation of life paths to better convey results of decision models to patients. <b>2015</b> , 35, 398-402	9
419	One-Year Outcomes of Emergency Department Patients With Atrial Fibrillation: A Prospective, Multicenter Registry in China. <b>2015</b> , 66, 745-52	8
418	Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation. <b>2015</b> , 37, 53-9	25
417	Left atrial appendage occlusion for stroke prevention. <b>2015</b> , 40, 429-76	6
416	La puntuaci3n CHADS2 como predictor de riesgo de ictus en 3ausencia de fibrilaci3n auricular en 3pacientes hipertensos de 65 o m3s a3os. <b>2015</b> , 68, 485-491	13
415	Poor adherence to anticoagulation guidelines in patients with non-valvular atrial fibrillation treated in a tertiary cardiology unit. <b>2015</b> , 7, 18-22	6
414	Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <b>2015</b> , 132, 624-32	159
413	Developing an Atrial Fibrillation Guideline Support Tool (AFGuST) for shared decision making. <b>2015</b> , 31, 603-14	27
412	Evaluation of oral anticoagulation therapy: rationale and design of the thromBEVAL study programme. <b>2015</b> , 22, 622-8	15
411	[Oral anticoagulation for non-valvular atrial fibrillation in the elderly]. <b>2015</b> , 50, 134-42	5
410	Efectividad y seguridad de anticoagulaci3n oral y antiagregaci3n luego de un evento cerebrovascular isqu3mico asociado a fibrilaci3n auricular no valvular. <b>2015</b> , 7, 3-10	1
409	[Interventional stroke prophylaxis : endocardial and epicardial left atrial appendage closure]. <b>2015</b> , 40, 50-9	0

408	Management of atrial fibrillation: What is new in the 2014 ACC/AHA/HRS guideline?. <b>2015</b> , 127, 396-404	1
407	Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service--results from the prospective, multi-center, observational cohort study thrombEVAL. <b>2015</b> , 13, 14	31
406	Edoxaban, a Novel Oral Factor Xa Inhibitor. <b>2015</b> , 49, 843-50	12
405	Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study. <b>2015</b> , 26, 508-14	15
404	Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study. <b>2015</b> , 131, 2176-84	362
403	The CHADS2 Score to Predict Stroke Risk in the Absence of Atrial Fibrillation in Hypertensive Patients Aged 65 Years or Older. <b>2015</b> , 68, 485-91	6
402	Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation. <b>2015</b> , 66, 677-88	102
401	Stroke Risk Stratification in Patients With Atrial Fibrillation: Comme Ci, Comme ȳ, Plus ȳ Changeȳȳ <b>2015</b> , 66, 1860-3	6
400	The Long-Term Use of Warfarin Among Atrial Fibrillation Patients Discharged From an Emergency Department With a Warfarin Prescription. <b>2015</b> , 66, 347-354.e2	27
399	Use of drug-eluting versus bare-metal stents after an acute coronary syndrome in Portugal: the EURHOBOP study. <b>2015</b> , 34, 449-56	4
398	Improving Anticoagulation Measurement Novel Warfarin Composite Measure. <b>2015</b> , 8, 600-7	8
397	Stroke with atrial fibrillation or atrial flutter: a descriptive population-based study from the Brest stroke registry. <b>2015</b> , 15, 63	7
396	Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <b>2015</b> , 169, 25-30	51
395	Management of Atrial Fibrillation. <b>2015</b> , 30, 484-98	5
394	The prestroke use of vitamin K antagonists for atrial fibrillation - trends over 15 years. <b>2015</b> , 69, 180-5	5
393	[Anticoagulation in atrial fibrillation in the elderly: the geriatrician point of view with a focus on the direct oral anticoagulants]. <b>2015</b> , 36, 22-30	7
392	Use of Vitamins K antagonists in non-valvular atrial fibrillation thromboembolic risk prevention in Burkina Faso. <b>2016</b> , 24, 108	7
391	Stroke Prevention with Percutaneous Left Atrial Appendage Closure. <b>2016</b> , 8, CMT.S18886	

390	Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAf) in the US. <b>2016</b> , 8, 215-26	13
389	Stroke as the First Manifestation of Atrial Fibrillation. <b>2016</b> , 11, e0168010	45
388	Embolism Risk Versus Stroke Risk: More Than a Matter of Semantics. <b>2016</b> , 64, 692-3	
387	Anticoagulation in atrial fibrillation and chronic heart failure: the risk and drug of choice. <b>2016</b> , 31, 229-34	9
386	How I use anticoagulation in atrial fibrillation. <b>2016</b> , 128, 2891-2898	8
385	Antithrombotic drug use: scientific breakthroughs, biological limits and physician behaviour. <b>2016</b> , 102, 1859-1860	2
384	Los nuevos anticoagulantes orales. <b>2016</b> , 23, 541-549	
383	Tratamiento farmacológico de la fibrilación auricular. Antiarrítmicos y anticoagulantes orales. <b>2016</b> , 16, 33-39	
382	Descripción de los pacientes con fibrilación auricular no valvular que ingresan al servicio de urgencias. <b>2016</b> , 23, 270-276	2
381	¿Son los nuevos anticoagulantes orales iguales a las antivitaminas K para la isquemia aguda de los miembros inferiores? Revisión sistemática de la evidencia. <b>2016</b> , 68, 123-126	
380	Secondary Prevention of Stroke with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Subanalysis of the J-RHYTHM Registry. <b>2016</b> , 25, 585-99	19
379	Trends in incidence and prevalence of hospitalization for atrial fibrillation and associated mortality in Western Australia, 1995-2010. <b>2016</b> , 208, 19-25	26
378	Florbetapir-PET to diagnose cerebral amyloid angiopathy: A prospective study. <b>2016</b> , 87, 2043-2049	59
377	How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <b>2016</b> , 181, 145-152	10
376	Novel oral anticoagulants in non-valvular atrial fibrillation: Pharmacological properties, clinical trials, guideline recommendations, new antidote drugs and real-world data. <b>2016</b> , 2, 167-173	3
375	Evaluation of a Prediction Model for the Development of Atrial Fibrillation in a Repository of Electronic Medical Records. <b>2016</b> , 1, 1007-1013	32
374	The great ESCAPE - a clinical pharmacologist's journey in stroke research. <b>2016</b> , 82, 334-9	1
373	Dielectric permittivity change detects the process of blood coagulation: Comparative study of dielectric coagulometry with rotational thromboelastometry. <b>2016</b> , 145, 3-11	4



372	Antiplatelet therapy for preventing stroke in people with atrial fibrillation. <b>2016,</b>	
371	European Society of Cardiology Guideline-Adherent Antithrombotic Treatment and Risk of Mortality in Asian Patients with Atrial Fibrillation. <b>2016, 6, 30734</b>	11
370	Monitoring and detecting atrial fibrillation using wearable technology. <b>2016, 2016, 3394-3397</b>	55
369	Stroke prevention. <b>2016, 45, e457-e471</b>	15
368	Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. <b>2016, 353, i2868</b>	86
367	Anticoagulantiebehandeling bij voorkamerfibrillatie. <b>2016, 45, 211-215</b>	
366	Initial Experience With High-Risk Patients Excluded From Clinical Trials: Safety of Short-Term Anticoagulation After Left Atrial Appendage Closure Device. <b>2016, 9,</b>	9
365	Paroxysmal Atrial Fibrillation: Novel Strategies for Monitoring and Implications for Treatment in Stroke. <b>2016, 18, 52</b>	5
364	Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Patients With Contraindications to Anticoagulation. <b>2016, 32, 1355.e9-1355.e14</b>	15
363	WITHDRAWN: Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm. <b>2016, CD003333</b>	
362	NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis. <b>2016, 3, e000279</b>	55
361	Individualized approaches to thromboprophylaxis in atrial fibrillation. <b>2016, 173, 143-58</b>	9
360	Secondary Prevention After Cardioembolic Stroke. <b>2016, 111-135</b>	
359	Emerging Tools for Stroke Prevention in Atrial Fibrillation. <b>2016, 4, 26-39</b>	9
358	Role of insertable cardiac monitors in anticoagulation therapy in patients with atrial fibrillation at high risk of bleeding. <b>2016, 18, 799-806</b>	15
357	Prior bleeding, future bleeding and stroke risk with oral anticoagulation in atrial fibrillation: What new lessons can ARISTOTLE teach us?. <b>2016, 175, 168-71</b>	1
356	Meta-analysis and adjusted indirect comparison of direct oral anticoagulants in prevention of acute limb ischemia in patients with atrial fibrillation. <b>2016, 32, 1167-73</b>	4
355	Intracranial Hemorrhage Risk in the Era of Antithrombotic Therapies for Ischemic Stroke. <b>2016, 18, 29</b>	12

354	Study design of J-ELD AF: A multicenter prospective cohort study to investigate the efficacy and safety of apixaban in Japanese elderly patients. <b>2016</b> , 68, 554-558	17
353	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). <b>2016</b> , 37, 267-315	3850
352	Safety of Uninterrupted Warfarin Therapy in Patients Undergoing Cardiovascular Endovascular Procedures: A Systematic Review and Meta-Analysis. <b>2016</b> , 278, 383-94	9
351	Management Strategies for Vitamin K Antagonists Reversal in Patients With Major Bleeding: A Survey of Italian Emergency Departments. <b>2017</b> , 23, 40-44	1
350	Antithrombotic agents intake prior to injury does not affect outcome after a traumatic brain injury in hospitalized elderly patients. <b>2017</b> , 38, 122-125	10
349	Meta-analysis of major bleeding events on aspirin versus vitamin K antagonists in randomized trials. <b>2017</b> , 230, 572-576	4
348	Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <b>2017</b> , 185, 140-149	31
347	Shifting Perceptions of Risk and Reward: Use of Anticoagulation in Patients With Acute Brain Ischemia and Atrial Fibrillation: Nine-Year Data From a National Acute Stroke Registry (National Acute Stroke Israeli Survey [NASIS]). <b>2017</b> , 48, 1092-1094	2
346	Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trial. <b>2017</b> , 43, 550-561	5
345	Replacing warfarin with a novel oral anticoagulant: Risk of recurrent bleeding and stroke in patients with warfarin ineligible or failure in patients with atrial fibrillation (The ROAR study). <b>2017</b> , 28, 853-861	6
344	Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?. <b>2017</b> , 282, 164-174	19
343	Evaluation of Apixaban for the Treatment of Nonvalvular Atrial Fibrillation With Regard to Dosing and Safety in a Community Hospital. <b>2017</b> , 33, 140-145	2
342	Risk of gastrointestinal bleeding during anticoagulant treatment. <b>2017</b> , 16, 673-685	31
341	Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). <b>2017</b> , 189, 40-47	40
340	Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. <b>2017</b> , 43, 365-379	62
339	Management of Atrial Fibrillation in Elderly Adults. <b>2017</b> , 65, 185-193	10
338	Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience. <b>2017</b> , 18, 467-477	6
337	Spinal subarachnoid and subdural hematoma presenting as a Brown-Squard-like myelopathy following minor trauma in a patient on dabigatran etexilate. <b>2017</b> , 12, 257-260	10

- 336 Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]). **2017**, 119, 1590-1595 26
- 335 Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. **2017**, 2, 525-534 13
- 334 Usefulness of a healthcare database for epidemiological research in atrial fibrillation. **2017**, 70, 169-179 13
- 333 Prognostic factors of clinical endpoints in elderly patients with atrial fibrillation during a 2-year follow-up in China: An observational cohort study. **2017**, 96, e7679 3
- 332 Embolic Stroke of Undetermined Source in Latin America: A Review. **2017**, 22, 171-181 6
- 331 Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis. *Journal of the American Heart Association*, **2017**, 6, 6 71
- 330 Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. **2017**, 89, 687-696 53
- 329 Risk of stroke in congestive heart failure with and without atrial fibrillation. **2017**, 248, 182-187 31
- 328 Editorial Commentary: Optimization of dose selection for nonvitamin K antagonist oral anticoagulants. **2017**, 27, 573-574
- 327 [Atrial fibrillation: Thromboembolic risk factor or marker? From concept to therapy]. **2017**, 46, 751-757
- 326 Oral anticoagulation for stroke prevention amongst atrial fibrillation patients with valvular heart disease: an update. **2017**, 32, 174-180 5
- 325 Intracranial Hemorrhage in Patients with Durable Mechanical Circulatory Support Devices: Institutional Review and Proposed Treatment Algorithm. **2017**, 108, 826-835 15
- 324 Once- or twice-daily non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of randomized controlled trials. **2017**, 116, 591-598 5
- 323 Bleeding With Direct Oral Anticoagulants: The Gastrointestinal Tract and Beyond. **2017**, 15, 1665-1667 3
- 322 Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice. **2017**, 11, 105-120 5
- 321 Rationale and design of ASSAF-K (A study of the safety and efficacy of anticoagulant therapy in the treatment of atrial fibrillation in Kanagawa). **2017**, 33, 111-116 0
- 320 Overview of the non-vitamin K oral anticoagulants for atrial fibrillation. **2017**, 11, 77-79
- 319 Effectiveness and safety of vitamin K antagonists and new anticoagulants in the prevention of thromboembolism in atrial fibrillation in older adults - a systematic review of reviews and the development of recommendations to reduce inappropriate prescribing. **2017**, 17, 223 10

318	Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. <b>2017</b> , 359, j5058		235
317	Semi-automatic left atrial appendage segmentation from 3D CCTA images. <b>2017</b> ,		
316	Interventional Left Atrial Appendage Closure: Focus on Practical Implications. <b>2017</b> ,		
315	Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study. <i>Annals of Internal Medicine</i> , <b>2017</b> , 167, 845-854	8	33
314	CHADS and CHADS-VASc Scores Predict the Risk of Ischemic Stroke Outcome in Patients with Interatrial Block without Atrial Fibrillation. <b>2017</b> , 24, 176-184		30
313	Risk of ischemic stroke after atrial fibrillation diagnosis: A national sample cohort. <b>2017</b> , 12, e0179687		21
312	Effectiveness and patient safety of platelet aggregation inhibitors in the prevention of cardiovascular disease and ischemic stroke in older adults - a systematic review. <b>2017</b> , 17, 225		6
311	Elevation of brain-enriched miRNAs in cerebrospinal fluid of patients with acute ischemic stroke. <b>2017</b> , 5, 24		44
310	Self-detection of atrial fibrillation in an aged population: three-year follow-up of the LietoAF intervention study. <b>2017</b> , 17, 218		5
309	Percutaneous Left Atrial Appendage Closure Devices. <b>2017</b> , 10, 1		3
308	New-onset atrial fibrillation: an update. <b>2018</b> , 32, 414-424		7
307	Development of an Algorithm for Stroke Prediction: A National Health Insurance Database Study in Korea. <b>2018</b> , 79, 214-220		9
306	Contemporary approach to stroke prevention in atrial fibrillation: Risks, benefits, and new options. <b>2018</b> , 28, 469-480		0
305	Use of non-vitamin K oral anticoagulants in people with atrial fibrillation and diabetes mellitus. <b>2018</b> , 35, 548-556		13
304	Contemporary utilization of antithrombotic therapy for stroke prevention in patients with atrial fibrillation: an audit in an Australian hospital setting. <b>2018</b> , 9, 97-111		6
303	Safety and Efficacy of Transcatheter Left Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation. <b>2018</b> , 60, 542-549		5
302	Regional variation in anticoagulation and clinical outcomes: scope for improvement. <b>2018</b> , 4, 152-154		2
301	[Spontaneous intraocular hemorrhage under oral anticoagulation : Apixaban in comparison to phenprocoumon]. <b>2018</b> , 115, 573-578		2

300	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion. <b>2018</b> , 20, 565-568		22
299	Less dementia with oral anticoagulation in atrial fibrillation. <b>2018</b> , 39, 453-460		131
298	Acute Management of Atrial Fibrillation: From Emergency Department to Cardiac Care Unit. <b>2018</b> , 36, 141-159		7
297	Use of Guidelines for Reducing Stroke Risk in Patients With Nonvalvular Atrial Fibrillation: A Review From a Latin American Perspective. <b>2018</b> , 24, 22-32		9
296	Atrial Fibrillation. <b>2018</b> , 724-735		
295	Prevention of Stroke in Atrial Fibrillation. <b>2018</b> , 1092-1100		
294	Voltammetric behavior of Mammeisin (MA) at a glassy carbon electrode and its interaction with Bovine Serum Albumin (BSA). <b>2018</b> , 119, 20-25		6
293	Left Atrial Appendage Occlusion/Exclusion: Procedural Image Guidance with Transesophageal Echocardiography. <b>2018</b> , 31, 454-474		23
292	Clarifying the management of new-onset atrial fibrillation. <b>2018</b> , 13, 585-587		
291	Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients. <b>2018</b> , 2, 1066-1075		9
290	Appropriate Use of Anticoagulation in Private Hospital Patients With Non-Valvular Atrial Fibrillation. <b>2018</b> , 27, S300-S301		
289	New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs. <b>2018</b> , 5, e000931		9
288	Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e010854	6	4
287	Neuroimaging and clinical outcomes of oral anticoagulant-associated intracerebral hemorrhage. <b>2018</b> , 84, 694-704		30
286	Atrial fibrillation and chronic kidney disease: A review of options for therapeutic anticoagulation to reduce thromboembolism risk. <b>2018</b> , 41, 1395-1402		13
285	Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges. <b>2018</b> , 48, 873-889		7
284	Left-Atrial Appendage Occluders: Recent Advances and Unresolved Issues. <b>2018</b> , 515-533		
283	Effect of Variation in Published Stroke Rates on the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation. <i>Annals of Internal Medicine</i> , <b>2018</b> , 169, 517-527	8	13

282	Newer technologies for detection of atrial fibrillation. <b>2018</b> , 363, k3946		29
281	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: A Retrospective Cohort Study. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e009263	6	27
280	Frequency of atrial thrombus formation in patients with atrial fibrillation under treatment with non-vitamin K oral anticoagulants in comparison to vitamin K antagonists: a systematic review and meta-analysis. <b>2018</b> , 23, 49		8
279	When Low-Risk Atrial Fibrillation Is Not So Low Risk: Beast of Burden. <b>2018</b> , 3, 558-560		10
278	Trend of Prevalence of Atrial Fibrillation and use of Oral Anticoagulation Therapy in Patients With Atrial Fibrillation in South Korea (2002-2013). <b>2018</b> , 28, 81-87		13
277	Diagnostic assessment of a deep learning system for detecting atrial fibrillation in pulse waveforms. <b>2018</b> , 104, 1921-1928		56
276	Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation. <b>2018</b> , 115, 287-294		11
275	Optimum Antithrombotic Therapy in Patients Requiring Long-Term Anticoagulation and Undergoing Percutaneous Coronary Intervention. <b>2018</b> , 2018, 5690640		1
274	Risk Factors. <b>2018</b> , 17-34		
273	Intermittent anticoagulation guided by continuous atrial fibrillation burden monitoring using dual-chamber pacemakers and implantable cardioverter-defibrillators: Results from the Tailored Anticoagulation for Non-Continuous Atrial Fibrillation (TACTIC-AF) pilot study. <b>2018</b> , 15, 1601-1607		25
272	How do anticoagulated atrial fibrillation patients who suffer ischemic stroke or spontaneous intracerebral hemorrhage differ?. <b>2018</b> , 41, 608-614		3
271	Appropriateness of oral anticoagulant therapy prescription and its associated factors in hospitalized older people with atrial fibrillation. <b>2018</b> , 84, 2010-2019		19
270	Evaluation of anticoagulation use and subsequent stroke in patients with atrial fibrillation after empiric surgical left atrial appendage closure: A retrospective case-control study. <b>2018</b> , 41, 1578-1582		11
269	Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75 mg twice daily administration. <b>2019</b> , 5, 17		3
268	Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. <b>2019</b> , 21, 1459-1467		24
267	A comparison of benign positional vertigo and stroke patients presenting to the emergency department with vertigo or dizziness. <b>2019</b> , 40, 102263		1
266	A Narrative Review of Nonvitamin K Antagonist Oral Anticoagulant Use in Secondary Stroke Prevention. <b>2019</b> , 28, 2363-2375		3
265	Simulation-Based Education for Physicians to Increase Oral Anticoagulants in Hospitalized Elderly Patients with Atrial Fibrillation. <b>2019</b> , 132, e634-e647		5

264	Screening for atrial fibrillation: Need for an integrated, structured approach. <b>2019</b> , 67, 33-35	9
263	Percutaneous devices for left atrial appendage occlusion: A contemporary review. <b>2019</b> , 11, 57-70	15
262	Oral Anticoagulant Type and Outcomes After Transcatheter Aortic Valve Replacement. <b>2019</b> , 12, 1566-1576	46
261	Pharmacologic and Nonpharmacologic Management of Atrial Fibrillation. <b>2019</b> , 103, 835-846	2
260	Smartwatch Based Atrial Fibrillation Detection from Photoplethysmography Signals. <b>2019</b> , 2019, 4306-4309	4
259	Ischemic and Bleeding Outcomes in Patients With Atrial Fibrillation and Contraindications to Oral Anticoagulation. <b>2019</b> , 5, 1384-1392	5
258	Atrial Fibrillation Detection from Wrist Photoplethysmography Signals Using Smartwatches. <b>2019</b> , 9, 15054	40
257	Directly Acting Oral Anticoagulants for the Prevention of Stroke in Atrial Fibrillation in England and Wales: Cost-Effectiveness Model and Value of Information Analysis. <b>2019</b> , 4, 2381468319866828	6
256	Medikamenteninduzierte gastrointestinale Blutung. <b>2019</b> , 14, 385-396	
255	Patent Foramen Ovale and Cryptogenic Stroke: Down the Hole!. <b>2019</b> , 143, 73-76	
254	Investigation on Dabigatran Etexilate and Worsening of Renal Function in Patients with Atrial fibrillation: The IDEA Study. <b>2019</b> , 39, 355-362	3
253	Can cerebral microbleeds predict stroke recurrence?. <b>2019</b> , 18, 619-620	
252	Prolonged Cardiac Rhythm Monitoring and Secondary Stroke Prevention in Patients With Cryptogenic Cerebral Ischemia. <b>2019</b> , 50, 2175-2180	28
251	Embolic strokes of undetermined source: theoretical construct or useful clinical tool?. <b>2019</b> , 12, 1756286419851381	14
250	Effect of direct oral anticoagulant for acute major cerebral artery occlusion in cardioembolic stroke/transient ischemic attack patients with non-valvular atrial fibrillation. <b>2019</b> , 402, 162-166	2
249	Left Atrial Occlusion Device Implantation: the Role of the Echocardiographer. <b>2019</b> , 21, 66	2
248	Oral anticoagulant monitoring: Are we on the right track?. <b>2019</b> , 41 Suppl 1, 40-48	4
247	Validation of a questionnaire measuring patient knowledge of atrial fibrillation in an Asian cohort. <b>2019</b> , 11, e011143	3

246	[Drug-induced gastrointestinal bleeding]. <b>2019</b> , 60, 597-607	8
245	Left atrial appendage closure: prevalence and risk of device-associated thrombus formation. <b>2019</b> , 9, 104-109	1
244	Atrial fibrillation and stroke: a practical guide. <b>2019</b> , 19, 208-224	13
243	Antiplatelet Drugs in the Management of Cerebral Ischemia. <b>2019</b> , 1031-1057	
242	Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update. <b>2019</b> , 34, 923-933	13
241	Direct oral anticoagulation and mortality in moderate to high-risk atrial fibrillation. <b>2019</b> , 105, 1487-1492	1
240	Quality of INR control and switching to non-Vitamin K oral anticoagulants between women and men with atrial fibrillation treated with Vitamin K Antagonists in Spain. A population-based, real-world study. <b>2019</b> , 14, e0211681	17
239	Twelve-month outcome in patients with stroke and atrial fibrillation not suitable to oral anticoagulant strategy: the WATCH-AF registry. <b>2019</b> , 6, e001187	2
238	Quality improvement of prescribing safety: a pilot study in primary care using UK electronic health records. <b>2019</b> , 69, 490	1
237	Potential Utility of Neurosonology in Paroxysmal Atrial Fibrillation Detection in Patients with Cryptogenic Stroke. <b>2019</b> , 8,	5
236	Geriatric Conditions and Prescription of Vitamin K Antagonists vs. Direct Oral Anticoagulants Among Older Patients With Atrial Fibrillation: SAGE-AF. <b>2019</b> , 6, 155	5
235	The Basics of Antithrombotic Medications. <b>2019</b> , 35, 55-71	
234	Association of Follow-Up Care With Long-Term Death and Subsequent Hospitalization in Patients With Atrial Fibrillation Who Receive Emergency Care in the Province of Ontario. <b>2019</b> , 12, e006498	1
233	Drug causes of intracerebral haemorrhage. <b>2019</b> , 318, 1231-1234	1
232	The more you look, the more you find: atrial fibrillation - nowhere to hide. <b>2019</b> , 34, 140-146	1
231	Secondary stroke prevention in atrial fibrillation: Still lacking pace?. <b>2019</b> , 284, 38-39	
230	Warfarin Dose and CYP2C Gene Cluster: An African Ancestral-Specific Variant Is a Strong Predictor of Dose in Black South African Patients. <b>2019</b> , 23, 36-44	8
229	An Economic Analysis of Stroke and Atrial Fibrillation. <b>2019</b> , 1-10	



228	The Translation of Knowledge Into Practice in the Management of Atrial Fibrillation in Singapore. <b>2019</b> , 28, 605-614		0
227	Shared parameter model for competing risks and different data summaries in meta-analysis: Implications for common and rare outcomes. <b>2020</b> , 11, 91-104		6
226	Geriatric Elements and Oral Anticoagulant Prescribing in Older Atrial Fibrillation Patients: SAGE-AF. <b>2020</b> , 68, 147-154		36
225	Non-inferiority Trial Design in Drug Development: A Primer for Cardiovascular Healthcare Professionals. <b>2020</b> , 20, 229-238		2
224	A consultant-led anticoagulation review of all patients in one clinical commissioning group to prevent atrial fibrillation related stroke. <b>2020</b> , 74, e13465		4
223	Platelet function in stroke/transient ischemic attack patients treated with tocotrienol. <b>2020</b> , 34, 11838-11843		2
222	Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study. <i>Annals of Internal Medicine</i> , <b>2020</b> , 172, 463-473	8	32
221	Percutaneous left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. <b>2020</b> , 15, FNL48		
220	World Caf <sup>®</sup> approach: exploring the future vision of oral anticoagulants for patients with atrial fibrillation (AF) in Ireland. <b>2020</b> , 10, e036493		
219	Stroke Prevention in Atrial Fibrillation: Looking Forward. <b>2020</b> , 142, 2371-2388		10
218	Is there a connection among atrial fibrillation, anticoagulant treatment, and dementia?. <b>2020</b> , 22, E79-E81		0
217	Non-inferiority trials in cardiology: what clinicians need to know. <b>2020</b> , 106, 99-104		4
216	A cost-effectiveness analysis model of Preventicus atrial fibrillation screening from the point of view of statutory health insurance in Germany. <b>2020</b> , 10, 16		7
215	Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China. <b>2020</b> , 42, 144-156.e1		2
214	Minor bleeding affects the level of knowledge in patients with atrial fibrillation on oral anticoagulant therapy. <b>2020</b> , 74, e13483		1
213	Brief episodes of rapid irregular atrial activity (micro-AF) are a risk marker for atrial fibrillation: a prospective cohort study. <b>2020</b> , 20, 167		3
212	Optimal Use of the Non-Inferiority Trial Design. <b>2020</b> , 34, 159-165		5
211	Fatal intracranial haemorrhage occurring after oral anticoagulant treatment initiation for secondary stroke prevention in patients with atrial fibrillation. <b>2020</b> , 27, 1612-1617		7

210	Medikamenteninduzierte gastrointestinale Blutung. <b>2020</b> , 42, 217-226	0
209	The Safety and Efficacy of Rivaroxaban Compared with Warfarin in Patients with Atrial Fibrillation and Diabetes: A Systematic Review and Meta-analysis. <b>2021</b> , 21, 51-61	4
208	'?' The relationship and the future of oral anticoagulation therapy versus LAA closure devices. <b>2021</b> , 19, 1-4	0
207	2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee. <b>2021</b> , 77, 629-658	45
206	Sociodemographic, behavioral, and clinical factors associated with low atrial fibrillation knowledge among older adults with atrial fibrillation: The SAGE-AF study. <b>2021</b> , 104, 194-200	1
205	Pharmacodynamics and Pharmacokinetics of Stroke Therapy. <b>2021</b> , 41-69	
204	Meta-analysis of metabolic syndrome and its individual components with risk of atrial fibrillation in different populations. <b>2021</b> , 21, 90	4
203	Interventional and pharmacological management of chronic thromboembolic pulmonary hypertension. <b>2021</b> , 177, 106293	2
202	Intracardiac echocardiography-guided implantation of the Watchman FLX left atrial appendage closure device. <b>2021</b> , 32, 717-725	4
201	Usefulness of transesophageal echocardiography before cardioversion in atrial arrhythmias. <b>2021</b> , 28, 101-109	5
200	Middle East Treatment Strategies and Clinical Outcomes in Patients with Atrial Fibrillation: One-Year Follow-up Data from Garfield-AF Study. <b>2021</b> , 38, 2391-2405	1
199	Current Drug Treatment Strategies for Atrial Fibrillation and TASK-1 Inhibition as an Emerging Novel Therapy Option. <b>2021</b> , 12, 638445	4
198	Blood pressure levels and risk of haemorrhagic stroke in patients with atrial fibrillation and oral anticoagulants: results from The Swedish Primary Care Cardiovascular Database of Skaraborg. <b>2021</b> , 39, 1670-1677	0
197	Screening and management of atrial fibrillation in primary care. <b>2021</b> , 373, n379	4
196	Beyond the 2020 guidelines on atrial fibrillation of the European society of cardiology. <b>2021</b> , 86, 1-11	12
195	Cardiopulmonary Emergencies in Older Adults. <b>2021</b> , 39, 323-338	0
194	A Questionnaire of 2020 European Society of Cardiology Atrial Fibrillation Guideline for Cardiologists.	
193	Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study. <b>2021</b> , 203, 121-130	2

192	Quarterly versus annual ECG screening for atrial fibrillation in older Chinese individuals (AF-CATCH): a prospective, randomised controlled trial. <b>2021</b> ,	2
191	Oral Anticoagulation and Adverse Outcomes after Ischemic Stroke in Heart Failure Patients without Atrial Fibrillation. <b>2021</b> , 27, 857-864	1
190	Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. <b>2021</b> , 398, 1498-1506	33
189	Anticoagulation after typical atrial flutter ablation: Systematic review and meta-analysis. <b>2021</b> , 44, 1701-1710	0
188	Understanding the Merits and Drawbacks of Noninferiority Trials in Cardiovascular Medicine. <b>2021</b> , 37, 1378-1393	1
187	High incidence of major bleeding with off-label use of edoxaban. <b>2021</b> , 69, 311-316	1
186	Inadequate oral anticoagulation with warfarin in women with cerebrovascular event and history of atrial fibrillation: the FibStroke study. <b>2021</b> , 53, 287-294	2
185	Antithrombotic Treatment and Cardioversion of Patients with Atrial Fibrillation. <b>2008</b> , 169-183	1
184	Atrial Fibrillation and Flutter. <b>2007</b> , 1955-1978	3
183	Anticoagulation Therapy of Atrial Fibrillation in the Elderly. <b>2003</b> , 329-334	1
182	Atrial Fibrillation. <b>2004</b> , 512-522	3
181	Management of cardiac arrhythmias. <b>2009</b> , 189-243	1
180	Anticoagulation for Atrial Fibrillation and Prosthetic Cardiac Valves. <b>2007</b> , 737-746	1
179	Left Atrial Appendage Thrombus in Transcatheter Aortic Valve Replacement: Incidence, Clinical Impact, and the Role of Cardiac Computed Tomography. <b>2017</b> , 10, 176-184	14
178	A collective European experience with left atrial appendage suture ligation using the LARIAT+ device. <b>2020</b> , 22, 924-931	3
177	Stroke in atrial fibrillation: a need for effective anticoagulation. <b>2004</b> , 97, 919-20	1
176	Clinical correlation between effective anticoagulants and risk of stroke: are we using evidence-based strategies?. <b>2004</b> , 97, 924-31	6
175	Using anticoagulation or aspirin to prevent stroke. Research was methodologically flawed. <b>2000</b> , 320, 1008-9; author reply 1010-1	3

174	Real-world characteristics of hospitalized frail elderly patients with atrial fibrillation: can we improve the current prescription of anticoagulants?. <b>2016</b> , 13, 226-32	25
173	Non-Traumatic Spontaneous Spinal Subdural Hematoma in a Patient with Non-Valvular Atrial Fibrillation During Treatment with Rivaroxaban. <b>2015</b> , 16, 377-81	27
172	Stroke policy and secondary prevention: how well are we adhering to these guidelines?. <b>2011</b> , 7, 684-690	2
171	Oral anticoagulation therapy in heart failure patients in sinus rhythm: a systematic review and meta-analysis. <b>2013</b> , 8, e52952	25
170	Determinants of left atrial appendage volume in stroke patients without chronic atrial fibrillation. <b>2014</b> , 9, e90903	7
169	Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in Taiwan: a nationwide cohort study. <b>2015</b> , 10, e0125257	20
168	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. <b>2016</b> , 11, e0164076	90
167	Anticoagulation in Atrial Fibrillation. <b>2012</b> , 1, 12-16	2
166	Stroke Prevention in Atrial Fibrillation - Outcomes and Future Directions. <b>2014</b> , 3, 194-200	1
165	Thrombolytic Therapy for Acute Ischemic Stroke: Past and Future. <b>2019</b> , 25, 242-250	13
164	A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes. <b>2019</b> , 25, 4063-4084	65
163	Understanding Atrial Fibrillation: The Signal Processing Contribution, Part I. <b>2008</b> , 3, 1-129	5
162	The evolution of anticoagulant therapy. <b>2016</b> , 14, 175-84	30
161	Anticoagulation in the Elderly. <b>2008</b> , 705-730	1
160	Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. <b>2017</b> , 21, 1-386	90
159	Atrial fibrillation in the elderly. <b>2012</b> , 9, 91-100	10
158	Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation. <b>2016</b> , 90, 189-197	4
157	Selecting antithrombotic therapy for patients with atrial fibrillation. <b>2015</b> , 82, 49-63	3

156	Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) III. <b>2014</b> , 3, 45-54	89
155	Incorporating Stroke and Bleeding Risk Stratification Tools into Atrial Fibrillation Management Making Sense of the Alphabet Soup. <b>2017</b> , 9, 1497	2
154	The Temporal Relationship Between Atrial Fibrillation and Ischemic Stroke. <b>2013</b> , 5, 738	1
153	Clinical Heart Failure Patients with Ischemic Stroke Have a High Incidence (>60%) of Atrial Fibrillation or Flutter Whether Systolic Function Is Preserved or Depressed. <b>2014</b> , 04, 455-464	1
152	Improving outpatient warfarin use for hospitalized patients with atrial fibrillation. <b>2008</b> , 6, 43-50	4
151	Present concepts in management of atrial fibrillation: From drug therapy to ablation. <b>2009</b> , 1, 11-22	6
150	Duration of Implantable Cardiac Monitoring and Detection of Atrial Fibrillation in Ischemic Stroke Patients: A Systematic Review and Meta-Analysis. <b>2019</b> , 21, 302-311	30
149	Association between anticoagulants and mortality and functional outcomes in older patients with major trauma. <b>2021</b> ,	
148	Deaths from cardiovascular disease involving anticoagulants: a systematic synthesis of coroners' case reports. <b>2021</b> ,	3
147	Nomogram to Predict Left Atrial Thrombus or Spontaneous Echo Contrast in Patients With Non-valvular Atrial Fibrillation. <b>2021</b> , 8, 737551	0
146	Comparison between Amulet and Watchman left atrial appendage closure devices: A real-world, single center experience. <b>2021</b> , 37, 100893	0
145	Antithrombotic therapy to prevent stroke in patients with atrial fibrillation. <i>Annals of Internal Medicine</i> , <b>2000</b> , 132, 841-2	8 1
144	Atrial Defibrillators. <b>2002</b> , 63-76	
143	?????????????. <b>2002</b> , 13, 141-150	1
142	Data and Safety Monitoring Boards. <b>2002</b> , 63-68	
141	Antiplatelet Agents for Prevention of Thromboembolism in Atrial Fibrillation: When, Why, and Which One?. <b>2002</b> , 422-435	2
140	[Secondary prevention of stroke]. <b>2003</b> , 40, 223-7	
139	Cerebral Embolism. <b>2003</b> , 300-309	

138 Breaks in continuity of care and the rural senior transferred for medical care under regionalisation. **2003**, 3, e03

4

137 Warfarin Underuse for Nonvalvular Atrial Fibrillation: How to Adjust Our Aims?. **2004**, 241-247

136 Herz, Gefäß, Lunge. **2004**, 81-196

135 ?????????????? SPORTIF III. **2004**, 15, 119-121

134 Secondary Prevention of Cardioembolic Stroke. **2004**, 1171-1186

133 What Is the Best Practical Scheme for Initiating Oral Anticoagulant Treatment in Outpatients with Atrial Fibrillation?. **2004**, 231-234

132 Use of Chronic Anticoagulation in the Elderly: A Review of the Benefits and Risks. **2004**, 181-199

131 Antikoagulation bei Herzerkrankungen. **2004**, 869-896

130 3. Monitoring Chronic Oral Anticoagulant Therapy in Cardiac Disease. **2005**, 637-648

129 Early Termination of the Stroke Prevention in Atrial Fibrillation I Trial: Protecting Participant Interests in the Face of Scientific Uncertainties and the Cruel Play of Chance. **2006**, 85-92

128 Complications of Atrial Fibrillation Ablation: How to Prevent and Manage Cerebrovascular Accidents. **2006**, 231-239

127 How Safe Is Anticoagulant Therapy in Older Patients and What Should Be the INR Target?. **2006**, 151-157

126 Antithrombotic Approaches in Cerebrovascular Disease. **2006**, 449-466

125 Anticoagulation and Antiplatelet Agents. **2006**, 501-524

124 Stroke Prevention. **2006**, 545-584

123 Data and Safety Monitoring Boards. **2007**, 59-65

122 Other Topics in Cardiology Consultation. **2007**, 124-150

121 Atrial fibrillation (AF) among patients of the Department of Cardiology in Lublin. **2008**, 63, 8-13

- 120 Antiplatelets and Anticoagulation in the Setting of Acute Heart Failure Syndrome. **2008**, 639-652
- 119 Neurological Manifestations of Acquired Cardiac Disease, Arrhythmias, and Interventional Cardiology. **2008**, 75-95
- 118 Arrhythmias. **2009**, 431-434
- 117 Acute Ischemic Stroke. **2009**, 571-640
- 116 NHG-Standaard TIA. **2009**, 449-464
- 115 Antithrombotic Therapy for Atrial Fibrillation and Cardioversion. **2010**, 389-403
- 114 Fatal thyrocardiac event. **2010**, 54, 255-8 o
- 113 Atrial Fibrillation and Heart Failure Syndromes. **2010**, 289-308
- 112 Pharmacologic Management of Atrial Fibrillation and Flutter. **2011**, 165-193
- 111 Value of trans-oesophageal echocardiography as a method of encouraging patients with chronic atrial fibrillation to use anticoagulation therapy. **2010**, 21, 192-4
- 110 Anticoagulation in the Older Surgical Patient. **2011**, 221-239
- 109 Secondary Prevention of Cardioembolic Stroke. **2011**, 1173-1191
- 108 NHG-Standaard TIA. **2011**, 537-552
- 107 Postoperative Cardiac Recovery and Outcomes. **2011**, 1010-1024 1
- 106 1.?????????????????????????????????????. **2011**, 42, 299-303
- 105 ??? ?????? II. ????. **2011**, 44, 405-411
- 104 Facteurs de risque emboliques et traitement antithrombotique pour la fibrillation atriale. **2011**, 195, 963-977
- 103 Minimally Invasive Surgical Implantation of the Percutaneous Left Atrial Appendage Transcatheter Occlusion Device Initial Experience in a Canine Model. **2012**, 7, 52-58

- 102 Anticoagulation in Atrial Arrhythmias. **2012**, 1175-1180
- 101 Anwendung und Grenzen in der Schlaganfallprävention. **2012**, 23, 42-47
- 100 Drugs for Thromboprophylaxis: Unfractionated Heparin, Low Molecular Weight Heparin, Warfarin, and Fondaparinux. **2013**, 53-65 2
- 99 Atrial Fibrillation: Current and Forthcoming Antithrombotic Therapies. 285-305
- 98 Detection and Management of Atrial Fibrillation in Patients with Stroke or TIA in Clinical Practice. **2014**, 221-236
- 97 Anticoagulants. **2014**, 73, 78-80
- 96 Gestion pharmaceutique des patients traités par antithrombotiques en chirurgie orale. Argumentaire. **2015**, 21, S15-S81 1
- 95 How to Understand Patent Foramen Ovale Clinical Significance - Part II: Therapeutic Strategies in Cryptogenic Stroke. **2015**, 25, 46-53 5
- 94 Percutaneous Coronary Intervention in Patients Who Have an Indication for Oral Anticoagulation - an Evidence-based Approach to Antithrombotic Therapy. **2015**, 10, 16-21
- 93 Introduction. **2016**, 1-6
- 92 Antiplatelet Therapy in Patients with Coronary Artery Disease. **2017**, 1361-1371
- 91 [Design of an atrial fibrillation and embolic risk registry in Mexico: CARMEN-AF]. **2017**, 87, 5-12 3
- 90 Cardioembolic Stroke. **2017**, 23, 111-132 9
- 89 ANTIVIRAL AND ANTICOAGULANT THERAPY IN A POLYMORBID PATIENT WITH CHRONIC VIRAL HEPATITIS C. TACTICS OF MANAGEMENT, FEATURES OF DRUG-DRUG INTERACTIONS. **2018**, 9-16
- 88 Ethnicity and Atrial Fibrillation: A Counterintuitive Phenomenon. **2018**, 125-136
- 87 Ischemic Stroke. **2018**, 827-918
- 86 Frequency of de novo atrial fibrillation in patients presenting with acute ischemic cerebrovascular stroke. **2020**, 72, 18
- 85 Anticoagulation therapy in patients with post-operative atrial fibrillation: Systematic review with meta-analysis. **2021**, 142, 106929



84	Association between Oral Anticoagulants and the Risk of Cardiogenic Thromboembolism in Patients with Atrial Fibrillation Undergoing Cancer Chemotherapy. <b>2020</b> , 2, 95-106	
83	Atrial Fibrillation. <b>2020</b> , 141-168	
82	Cardiac Dysrhythmias. <b>2020</b> , 141-163	
81	Pharmacologic Management of Atrial Fibrillation and Flutter. <b>2020</b> , 359-407	
80	Prevention of ischemic stroke in atrial fibrillation from the point of view of a neurologist. Standards and real clinical practice. <b>2021</b> , 93, 1240-1245	
79	Gastrointestinal Bleeding: a Cardiologist's Point of View. <b>2021</b> , 17, 771-778	
78	Nichtmedikamentöse Verfahren zur Verhinderung kardialer Embolien. <b>2007</b> , 157-166	
77	Guidelines for Anticoagulation of Atrial Fibrillation: Is It Time for an Update?. <b>2006</b> , 169-176	
76	Reducing Cardioembolic Events. <b>2008</b> , 25-45	
75	Literatur. <b>2008</b> , 187-196	
74	Seasonal Variations in the Incidence of Ischemic Stroke, Extracranial and Intracranial Hemorrhage in Atrial Fibrillation Patients. <b>2020</b> , 84, 1701-1708	1
73	Role of Remote Monitoring in Detection of Atrial Arrhythmia, Stroke Reduction, and Use of Anticoagulation Therapy - A Systematic Review and Meta-Analysis. <b>2020</b> , 84, 1922-1930	0
72	[Management of hemostasis in gastroenterology critical care]. <b>2020</b> , 58, 1099-1106	1
71	Anticoagulation therapy for patients with atrial fibrillation. <b>2000</b> , 163, 956-7	2
70	Long term anticoagulation or antiplatelet treatment. Only warfarin has been shown to reduce stroke risk in patients with atrial fibrillation. <b>2001</b> , 323, 233; author reply 235-6	
69	Identification of stroke in the community: a comparison of three methods. <b>2003</b> , 53, 520-4	7
68	Rate-control or rhythm-control: where do we stand?. <b>2005</b> , 5, 296-304	3
67	Importance of risk communication and decision making in cardiovascular conditions in older patients: a discussion paper. <b>2001</b> , 10 Suppl 1, i19-22	10

66	Management of atrial fibrillation. <b>2007</b> , 3, 109-16	9
65	Synchronised cardioversion for chronic atrial fibrillation. <b>2008</b> , 42, 29-32	
64	Stroke Best Practices: a team approach to evidence-based care. <b>2004</b> , 96, 5S-20S	2
63	Stroke prevention in nonvalvular atrial fibrillation. <b>2011</b> , 38, 350-2	3
62	New antithrombotic drugs: a revolution in stroke management. <b>2012</b> , 23, 61-2	
61	Management of atrial fibrillation in patients undergoing percutaneous coronary intervention. <b>2014</b> , 9, 33-7	1
60	Extensive bilateral vertebral artery remodeling following treatment of dissection using pipeline embolic device. <b>2014</b> , 7, 5-8	8
59	A practical approach to the management of patients with atrial fibrillation. <b>2010</b> , 2, 95-103	1
58	Stroke Prevention in Atrial Fibrillation. <b>2010</b> , 3, 279	1
57	The Cost of Thromboembolic Events and their Prevention among Patients with Atrial Fibrillation. <b>2011</b> , 3, 340	
56	Efficacy And Safety of Dabigatran Etxilate Utilization With Concomitant Dual Antiplatelet Therapy In Atrial Fibrillation. <b>2014</b> , 6, 1001	
55	Dabigatran, A Direct Thrombin Inhibitor, In Atrial Fibrillation: Is It Already Time For A Change In Oral Anticoagulation Therapy?. <b>2010</b> , 2, 234	
54	The Atrial Fibrillation Therapies after ER visit: Outpatient Care for Patients with Acute AF - The AFTER3 Study. <b>2015</b> , 7, 1187	6
53	Role of Echocardiography in the Management and Prognosis of Atrial Fibrillation. <b>2012</b> , 4, 463	
52	Comparing Antiarrhythmic Drugs and Catheter Ablation for Treatment of Atrial Fibrillation. <b>2013</b> , 6, 861	1
51	Apixaban in patients with Atrial Fibrillation: A Systematic Review. <b>2012</b> , 5, 499	
50	Solutions to Reduce Cardiovascular Events in Patients with Atrial Fibrillation. <b>2012</b> , 5, 672	
49	High Incidence of Atrial Fibrillation or Flutter in Stroke Patients Who Have the Clinical Risk Factors for Stroke. <b>2013</b> , 6, 881	1

48	Prevalence of Valvular and Non-valvular Atrial Fibrillation and the Application of Antithrombotic Treatment in a Tertiary Care Hospital. <b>2020</b> , 58, 851-855	
47	Assessment of histological characteristics, imaging markers, and rt-PA susceptibility of ex vivo venous thrombi. <b>2021</b> , 11, 22805	0
46	Screening for Atrial Fibrillation in Sub-Saharan Africa: A Health Economic Evaluation to Assess the Feasibility in Nigeria.. <b>2021</b> , 16, 80	
45	Prevalence of Valvular and Non-valvular Atrial Fibrillation and the Application of Antithrombotic Treatment in a Tertiary Care Hospital. <b>2020</b> , 58, 851-855	
44	The prevalence of atrial fibrillation in Greenland: a register-based cross-sectional study based on disease classifications and prescriptions of oral anticoagulants.. <b>2022</b> , 81, 2030522	2
43	The Relationship Between Limited English Proficiency and Outcomes in Stroke Prevention, Management, and Rehabilitation: A Systematic Review.. <b>2022</b> , 13, 790553	0
42	The Year in Electrophysiology: Selected Highlights from 2021.. <b>2022</b> ,	
41	Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension.. <b>2022</b> ,	3
40	Direct costs in patients with nonvalvular atrial fibrillation newly indicated to apixaban: a retrospective-prospective single-arm cohort study. <b>2022</b> , 68, 26-33	
39	Risk of Death and Ischemic Stroke in Patients with Atrial Arrhythmia and Thrombus or Sludge in Left Atrial Appendage at One-Year Follow-Up.. <b>2022</b> , 11,	1
38	Cost-effectiveness of a photoplethysmographic procedure for screening for atrial fibrillation in 6 European countries.. <b>2022</b> , 12, 17	0
37	Use and Prescription of Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Multidisciplinary Consensus Document.. <b>2022</b> , 12,	1
36	Characteristics of non-valvular atrial fibrillation with left atrial appendage thrombus who are undergoing appropriate oral anticoagulation therapy. 1	0
35	Early recurrence of ischaemic stroke of cardioembolic cause and delayed anticoagulation: a case report.. <b>2022</b> , 11,	
34	Association between Body Mass Index and Clinical Outcomes in Patients with Non-valvular Atrial Fibrillation Receiving Direct Oral Anticoagulants: A New Piece of Evidence on the Obesity Paradox from China.. <b>2022</b> , 1	0
33	Atrial fibrillation.. <b>2022</b> , 8, 21	5
32	Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation: Rationale and Design of the RED-AF study.. <b>2022</b> , 248, 42-42	0
31	Predictors of Subsequent Heart Failure After Left Atrial Appendage Closure. <b>2021</b> ,	1

- 30 Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Bioprosthetic Valves-A Systematic Review and Meta-analysis.. **2021**, 12, 4797-4805
- 29 Off-label direct oral anticoagulants dosing in atrial fibrillation and venous thromboembolism is associated with higher mortality. **2021**, ○
- 28 Cardioembolic stroke: classification of causes and prevention strategies. **2021**, 13, 4-13
- 27 Table\_1.DOCX. **2019**,
- 26 Importance of risk communication and decision making in cardiovascular conditions in older patients: a discussion paper. **2001**, 10, i19-i22 9
- 25 ???(Efficacy of protocol for the safe use of prothrombin complex concentrate in patients with severe bleeding event on anticoagulant therapy). *Nihon Kyukyū Igakukai Zasshi*, **2020**, 31, 126-131 ○
- 24 Ischemic Stroke – Post Stroke Management of Anticoagulation. **2022**, 99-104
- 23 In Search of the Optimal Antithrombotic Regimen for Intracerebral Hemorrhage Survivors with Atrial Fibrillation. *Drugs*, 12.1
- 22 Neurological Complications of Anticoagulation. **2022**, 549-560
- 21 High Prevalence of Atrial Fibrillation in a Lithuanian Stroke Patient Cohort. *Medicina (Lithuania)*, **2022**, 58, 800 3.1 ○
- 20 Assessment of Cardiac Electrical Activity in Patients with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. *SSRN Electronic Journal*, 1
- 19 Trends in Uptake and Adherence to Oral Anticoagulation for Patients With Incident Atrial Fibrillation at High Stroke Risk Across Health Care Settings. *Journal of the American Heart Association*, 6 1
- 18 Changes in primary care management of atrial fibrillation patients following the shift from warfarin to non-vitamin K antagonist oral anticoagulants: a Norwegian population based study. **2022**, 23,
- 17 Left Atrial Appendage Occlusion Versus Anticoagulation in Atrial Fibrillation: Equipoise When Bleeding Risk Is High.
- 16 Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. **2022**, 3
- 15 Left Atrial Appendage Closure for Stroke Prevention.
- 14 Vorhofflimmern. **2022**, 111, 640-652
- 13 Sensitivity and specificity of automated blood pressure devices to detect atrial fibrillation: A systematic review and meta-analysis of diagnostic accuracy. 9, ○

- 12 A descriptive cross-sectional study of self-management in patients with nonvalvular atrial fibrillation. **2022**, 101, e30781
- 11 Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease.
- 10 Introduction to Atrial Fibrillation. **2008**, 3-32
- 9 Impact of Left Atrial or Left Atrial Appendage Thrombus on Stroke Outcome: A Matched Control Analysis.
- 8 Fibrinogen, Coagulation, and Ageing. **2023**, 313-342
- 7 Is there still room for warfarin after the appearance of direct oral anticoagulants?. **2023**, 12, 32-42
- 6 Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D.
- 5 Artificial intelligence-enabled mobile electrocardiograms for event prediction in paroxysmal atrial fibrillation. **2023**,
- 4 The first experience of a hybrid approach in the surgical treatment of atrial fibrillation. **2023**, 13, 38-50
- 3 Postoperative atrial fibrillation: from mechanisms to treatment.
- 2 Challenges of Anticoagulant Therapy in Atrial Fibrillation—Focus on Gastrointestinal Bleeding. **2023**, 24, 6879
- 1 Treatment of Persistent Left Atrial Appendage Thrombus in Patients with Atrial Fibrillation on Adequate Oral Anticoagulation: Pathways of Care for All-comers and Heart Failure Patients. 9,